18,789,190 results on '"female"'
Search Results
2. The Dose–Response in Elite Soccer: Preliminary Insights From Menstrual-Cycle Tracking During the FIFA Women's World Cup 2019.
- Author
-
Scott, Dawn, Bruinvels, Georgie, Norris, Dean, and Lovell, Ric
- Subjects
SELF-evaluation ,STATISTICAL models ,SOCCER ,WOMEN ,MUSCULOSKELETAL pain ,FATIGUE (Physiology) ,INDUSTRIAL psychology ,PHYSICAL training & conditioning ,DOSE-response relationship in biochemistry ,HEART beat ,SLEEP duration ,MENSTRUAL cycle ,SPORTS events ,SLEEP ,CONTRACEPTIVE drugs ,ALGORITHMS - Abstract
Purpose: This preliminary study examined the influence of estimated menstrual-cycle (MC) phase on responses to soccer matches and training sessions in preparation for and during the FIFA (Fédération internationale de football association) Women's World Cup 2019. Methods: Twenty outfield players representing a national team were tracked over a 45-day period. External (10-Hz global positioning system; total and distance covered at high-metabolic power [≥20 W·kg
−1 ]) and internal load measures (minutes ≥80% heart-rate maximum, sessional ratings of perceived exertion) were collected during all training and matches, with single-item wellness measures (fatigue, soreness, sleep quality, and sleep duration) collected each morning prior to activity. MC phase was estimated individually via an algorithm, informed from pretournament survey responses and ongoing symptom reporting (FitrWoman). Model comparison statistics were used to determine the impact of estimated MC phase in nonhormonal contraceptive users (n = 16). Results: Sessional rating of perceived exertion responses to total distances ≥5 km were higher during the luteal phase (+0.6–1.0 au; P ≤.0178) versus menstruation (phase 1), but no other observable dose–response trends were observed. Sleep, fatigue, and soreness ratings were not typically associated with MC phase, with the exception of exacerbated fatigue ratings in luteal versus follicular phase 48 hours postmatch (−0.73 au, P =.0275). Conclusions: Preliminary findings suggest that estimated MC phase may contribute to the understanding of the dose–response to soccer training and matches. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. Long-Term Dementia Risk in Parkinson Disease.
- Author
-
Gallagher, Julia, Gochanour, Caroline, Caspell-Garcia, Chelsea, Dobkin, Roseanne, Aarsland, Dag, Alcalay, Roy, Barrett, Matthew, Chahine, Lana, Chen-Plotkin, Alice, Coffey, Christopher, Dahodwala, Nabila, Eberling, Jamie, Espay, Alberto, Leverenz, James, Litvan, Irene, Mamikonyan, Eugenia, Morley, James, Richard, Irene, Rosenthal, Liana, Siderowf, Andrew, Simuni, Tatyana, York, Michele, Willis, Allison, Xie, Sharon, and Weintraub, Daniel
- Subjects
Humans ,Parkinson Disease ,Dementia ,Male ,Female ,Aged ,Middle Aged ,Prospective Studies ,Cohort Studies ,Risk Factors ,Disease Progression ,Neuropsychological Tests ,Mental Status and Dementia Tests - Abstract
BACKGROUND AND OBJECTIVES: It is widely cited that dementia occurs in up to 80% of patients with Parkinson disease (PD), but studies reporting such high rates were published over two decades ago, had relatively small samples, and had other limitations. We aimed to determine long-term dementia risk in PD using data from two large, ongoing, prospective, observational studies. METHODS: Participants from the Parkinsons Progression Markers Initiative (PPMI), a multisite international study, and a long-standing PD research cohort at the University of Pennsylvania (Penn), a single site study at a tertiary movement disorders center, were recruited. PPMI enrolled de novo, untreated PD participants and Penn a convenience cohort from a large clinical center. For PPMI, a cognitive battery is administered annually, and a site investigator makes a cognitive diagnosis. At Penn, a comprehensive cognitive battery is administered either annually or biennially, and a cognitive diagnosis is made by expert consensus. Interval-censored survival curves were fit for time from PD diagnosis to stable dementia diagnosis for each cohort, using cognitive diagnosis of dementia as the primary end point and Montreal Cognitive Assessment (MoCA) score
- Published
- 2024
4. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
- Author
-
Miller, Phoebe, Romero-Hernandez, Fernanda, Calthorpe, Lucia, Wang, Jaeyun, Kim, Sunhee, Corvera, Carlos, Hirose, Kenzo, Kirkwood, Kimberly, Hirose, Ryutaro, Maker, Ajay, Alseidi, Adnan, Adam, Mohamed, Kim, Grace, Tempero, Margaret, Ko, Andrew, and Nakakura, Eric
- Subjects
Humans ,Pancreatic Neoplasms ,Neoadjuvant Therapy ,Antineoplastic Combined Chemotherapy Protocols ,Male ,Female ,Retrospective Studies ,Leucovorin ,Irinotecan ,Fluorouracil ,Survival Rate ,Middle Aged ,Oxaliplatin ,Aged ,Follow-Up Studies ,Prognosis ,Pancreatectomy ,Carcinoma ,Pancreatic Ductal ,Adult - Abstract
BACKGROUND: In 2023 alone, its estimated that over 64,000 patients will be diagnosed with PDAC and more than 50,000 patients will die of the disease. Current guidelines recommend neoadjuvant therapy for patients with borderline resectable and locally advanced PDAC, and data is emerging on its role in resectable disease. Neoadjuvant chemotherapy may increase the number of patients able to receive complete chemotherapy regimens, increase the rate of microscopically tumor-free resection (R0) margin, and aide in identifying unfavorable tumor biology. To date, this is the largest study to examine surgical outcomes after long-duration neoadjuvant chemotherapy for PDAC. METHODS: Retrospective analysis of single-institution data. RESULTS: The routine use of long-duration therapy in our study (median cycles: FOLFIRINOX = 10; gemcitabine-based = 7) is unique. The majority (85%) of patients received FOLFIRINOX without radiation therapy; the R0 resection rate was 76%. Median OS was 41 months and did not differ significantly among patients with resectable, borderline-resectable, or locally advanced disease. CONCLUSIONS: This study demonstrates that in patients who undergo surgical resection after receipt of long-duration neoadjuvant FOLFIRINOX therapy alone, survival outcomes are similar regardless of pretreatment resectability status and that favorable surgical outcomes can be attained.
- Published
- 2024
5. Extraskeletal Ewing Sarcoma of the Gastrointestinal and Hepatobiliary Tract: Deceptive Immunophenotype Commonly Leads to Misdiagnosis.
- Author
-
Shiyanbola, Oyewale, Nigdelioglu, Recep, Dhall, Deepti, González, Iván, Warmke, Laura, Schechter, Shula, Choi, Won-Tak, Hu, Shaomin, Voltaggio, Lysandra, Zhang, Yujie, Liang, Tom, Ko, Huaibin, Charville, Greg, and Longacre, Teri
- Subjects
Humans ,Male ,Diagnostic Errors ,Female ,Sarcoma ,Ewing ,Adult ,Middle Aged ,Gastrointestinal Neoplasms ,Retrospective Studies ,Biliary Tract Neoplasms ,Biomarkers ,Tumor ,Adolescent ,Young Adult ,Child ,Child ,Preschool ,Immunohistochemistry ,Liver Neoplasms ,Immunophenotyping ,RNA-Binding Protein EWS ,Predictive Value of Tests - Abstract
Ewing sarcoma (ES) is an uncommon mesenchymal neoplasm that typically develops as a bone mass, although up to 30% arise in extraskeletal sites. ES of the gastrointestinal (GI) and hepatobiliary tract is rare and may be misdiagnosed as other, more common neoplasms that occur in these sites. However, the correct classification of extraskeletal ES is important for timely clinical management and prognostication. We reviewed our experience of ES in the GI and hepatobiliary tract in order to further highlight the clinicopathologic features of these neoplasms and document the potential for misdiagnosis in this setting. The archives and consultation files of 6 academic institutions were retrospectively queried for cases of ES occurring in the GI and hepatobiliary tract. The histologic slides and ancillary studies were reviewed and clinical data were retrieved for each case through the electronic medical records, when available. Twenty-three patients with ES in the GI and/or hepatobiliary tract were identified from 2000 to 2022. Of these, 11 were women and 12 were men with a median age of 38 years (range, 2 to 64). Tumor locations included the pancreas (n=5), liver (n=2), stomach (n=3), colorectum (n=3), and small intestine (n=5), as well as tumors involving multiple organs, pelvis and retroperitoneum (n=5). Tumor size varied between 2 cm and 18 cm. Twenty were primary and 3 were metastases. Of the 23 cases, only 17% were initially diagnosed as ES. The most common misdiagnoses involved various forms of neuroendocrine neoplasia due to expression of synaptophysin and other neuroendocrine markers (22%). A wide variety of diagnoses including GI stromal tumor was considered due to aberrant CD117 expression (4%). The diagnosis of ES was ultimately confirmed by detection of the EWSR1 rearrangement in 22 cases. The remaining case was diagnosed using traditional immunohistochemistry. Follow-up information was available in 20 cases, with follow-up time varying between 2 and 256 months. Six patients with follow-up died of disease between 6 and 60 months following initial presentation. Our data indicate ES in the GI and hepatobiliary tract is commonly misdiagnosed leading to a delay in therapy. In light of the attendant therapeutic and prognostic implications, ES should be considered in the differential diagnosis of any GI or hepatobiliary tumor with epithelioid and/or small round cell morphology.
- Published
- 2024
6. Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody
- Author
-
Cox, Kristin E, Turner, Michael A, Lwin, Thinzar M, Amirfakhri, Siamak, Kelly, Kaitlyn J, Hosseini, Mojgan, Ghosh, Pradipta, Obonyo, Marygorret, Hoffman, Robert M, Yazaki, Paul J, and Bouvet, Michael
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Orphan Drug ,Rare Diseases ,Digestive Diseases ,5.1 Pharmaceuticals ,Stomach Neoplasms ,Animals ,Humans ,Mice ,Carcinoembryonic Antigen ,Adenocarcinoma ,Xenograft Model Antitumor Assays ,Antibodies ,Monoclonal ,Humanized ,Fluorescent Dyes ,Tumor Cells ,Cultured ,Female ,Indoles ,Optical Imaging ,Gastrectomy ,Mice ,Nude ,Cell Line ,Tumor ,Gastric cancer ,Patient-derived orthotopic xenograft ,PDOX ,Fluorescence ,Fluorescent antibody ,CEA ,Tumor targeting ,Tumor labeling ,Gastric cancer ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundGastric cancer poses a major diagnostic and therapeutic challenge as surgical resection provides the only opportunity for a cure. Specific labeling of gastric cancer could distinguish resectable and nonresectable disease and facilitate an R0 resection, which could improve survival.MethodsTwo patient-derived gastric cancer lines, KG8 and KG10, were established from surgical specimens of two patients who underwent gastrectomy for gastric adenocarcinoma. Harvested tumor fragments were implanted into the greater curvature of the stomach to establish patient-derived orthotopic xenograft (PDOX) models. M5A (humanized anti-CEA antibody) or IgG control antibodies were conjugated with the near-infrared dye IRDye800CW. Mice received 50 µg of M5A-IR800 or 50 µg of IgG-IR800 intravenously and were imaged after 72 hr. Fluorescence imaging was performed by using the LI-COR Pearl Imaging System. A tumor-to-background ratio (TBR) was calculated by dividing the mean fluorescence intensity of the tumor versus adjacent stomach tissue.ResultsM5A-IR800 administration resulted in bright labeling of both KG8 and K10 tumors. In the KG8 PDOX models, the TBR for M5A-IR800 was 5.85 (SE ± 1.64) compared with IgG-IR800 at 0.70 (SE ± 0.17). The K10 PDOX models had a TBR of 3.71 (SE ± 0.73) for M5A-IR800 compared with 0.66 (SE ± 0.12) for IgG-IR800.ConclusionsHumanized anti-CEA (M5A) antibodies conjugated to fluorescent dyes provide bright and specific labeling of gastric cancer PDOX models. This tumor-specific fluorescent antibody is a promising potential clinical tool to detect the extent of disease for the determination of resectability as well as to visualize tumor margins during gastric cancer resection.
- Published
- 2024
7. Metabolic Perturbations Associated with both PFAS Exposure and Perinatal/Antenatal Depression in Pregnant Individuals: A Meet-in-the-Middle Scoping Review
- Author
-
Suthar, Himal, Tanghal, Roselyn B, Chatzi, Lida, Goodrich, Jesse A, Morello-Frosch, Rachel, and Aung, Max
- Subjects
Midwifery ,Health Sciences ,Prevention ,Perinatal Period - Conditions Originating in Perinatal Period ,Endocrine Disruptors ,Pregnancy ,Pediatric ,Mental Health ,Depression ,Brain Disorders ,Women's Health ,Maternal Health ,Mental Illness ,Clinical Research ,2.1 Biological and endogenous factors ,Mental health ,Reproductive health and childbirth ,Good Health and Well Being ,Humans ,Female ,Environmental Pollutants ,Fluorocarbons ,Maternal Exposure ,Metabolome ,Pregnancy Complications ,Metabolomics ,Per- and poly-fluoroalkyl substances ,Metabolic pathways ,Epidemiology ,Public health - Abstract
Purpose of reviewDepression during the perinatal or antenatal period affects at least 1 in 10 women worldwide, with long term health implications for the mother and child. Concurrently, there is increasing evidence associating maternal exposure to per- and poly-fluoroalkyl substances (PFAS) to adverse pregnancy outcomes. We reviewed the body of evidence examining both the associations between PFAS exposure and perturbations in the maternal metabolome, and the associations between the maternal metabolome and perinatal/antenatal depression. Through this, we sought to explore existing evidence of the perinatal metabolome as a potential mediation pathway linking PFAS exposure and perinatal/antenatal depression.Recent findingsThere are few studies examining the metabolomics of PFAS exposure-specifically in pregnant women-and the metabolomics of perinatal/antenatal depression, let alone studies examining both simultaneously. Of the studies reviewed (N = 11), the majority were cross sectional, based outside of the US, and conducted on largely homogenous populations. Our review identified 23 metabolic pathways in the perinatal metabolome common to both PFAS exposure and perinatal/antenatal depression. Future studies may consider findings from our review to conduct literature-derived hypothesis testing focusing on fatty acid metabolism, alanine metabolism, glutamate metabolism, and tyrosine metabolism when exploring the biochemical mechanisms conferring the risk of perinatal/antenatal depression due to PFAS exposure. We recommend that researchers also utilize heterogenous populations, longitudinal study designs, and mediation approaches to elucidate key pathways linking PFAS exposures to perinatal/antenatal depression.
- Published
- 2024
8. Advancing Understanding of Chemical Exposures and Maternal-child Health Through the U.S. Environmental Influences on Child Health Outcomes (ECHO) Program: A Scoping Review.
- Author
-
Barrett, Emily, Ames, Jennifer, Eick, Stephanie, Peterson, Alicia, Rivera-Núñez, Zorimar, Starling, Anne, and Buckley, Jessie
- Subjects
Chemical exposures ,Children’s health ,ECHO ,Pregnancy ,Humans ,Child Health ,United States ,Female ,Pregnancy ,Environmental Exposure ,Child ,Prenatal Exposure Delayed Effects ,Environmental Pollutants ,Maternal Exposure ,Child ,Preschool ,Child Development ,Infant ,Maternal Health - Abstract
PURPOSE OF REVIEW: Environmental chemical exposures may disrupt child development, with long-lasting health impacts. To date, U.S. studies of early environmental exposures have been limited in size and diversity, hindering power and generalizability. With harmonized data from over 60,000 participants representing 69 pregnancy cohorts, the National Institutes of Healths Environmental influences on Child Health Outcomes (ECHO) Program is the largest study of U.S. childrens health. Here, we: (1) review ECHO-wide studies of chemical exposures and maternal-child health; and (2) outline opportunities for future research using ECHO data. RECENT FINDINGS: As of early 2024, in addition to over 200 single-cohort (or award) papers on chemical exposures supported by ECHO, ten collaborative multi-cohort papers have been made possible by ECHO data harmonization and new data collection. Multi-cohort papers have examined prenatal exposure to per- and polyfluoroalkyl substances (PFAS), phthalates, phenols and parabens, organophosphate esters (OPEs), metals, melamine and aromatic amines, and emerging contaminants. They have primarily focused on describing patterns of maternal exposure or examining associations with maternal and infant outcomes; fewer studies have examined later child outcomes (e.g., autism) although follow up of enrolled ECHO children continues. The NICHDs Data and Specimen Hub (DASH) database houses extensive ECHO data including over 470,000 chemical assay results and complementary data on priority outcome areas (pre, peri-, and postnatal, airway, obesity, neurodevelopment, and positive health), making it a rich resource for future analyses. ECHOs extensive data repository, including biomarkers of chemical exposures, can be used to advance our understanding of environmental influences on childrens health. Although few published studies have capitalized on these unique harmonized data to date, many analyses are underway with data now widely available.
- Published
- 2024
9. From targets to solutions: Implementing a trauma quality improvement bundle in Cameroon
- Author
-
Zheng, Dennis J, Yost, Mark T, Mbuh, Lidwine N, Tchekep, Mirene, Boumsong, Jean Baptiste, Tsiagadigui, Jean Gustave, Oke, Rasheedat, Juillard, Catherine, Chichom-Mefire, Alain, and Christie, S Ariane
- Subjects
Health Services and Systems ,Health Sciences ,Clinical Research ,8.1 Organisation and delivery of services ,Humans ,Cameroon ,Quality Improvement ,Wounds and Injuries ,Male ,Female ,Resuscitation ,Trauma Centers ,Checklist ,Adult ,Patient Care Bundles ,Emergency medicine ,Global surgery ,Injury ,Quality improvement ,Sub-Saharan Africa ,Trauma surgery ,Clinical Sciences ,Nursing ,Public Health and Health Services ,Orthopedics ,Biomedical and clinical sciences ,Clinical sciences ,Dentistry ,Health sciences - Abstract
BackgroundGlobal surgery research efforts have been criticized for failure to transition from problem identification to intervention implementation. We developed a context-appropriate trauma quality improvement (TQI) bundle to ameliorate care gaps at a regional referral hospital in Cameroon. We determined associations between bundle implementation and improvement in trauma resuscitation practices.MethodsWe implemented a TQI bundle consisting of a hospital-specific trauma protocol, staff training, a trauma checklist, provision of essential emergency trauma supplies in the resuscitation area, and monthly quality improvement meetings. We compared trends in target process measures (e.g., frequency and timing of vital sign collection and primary survey interventions) in the six-month period pre- and post-bundle implementation using Wilcoxon rank-sum and Fisher's exact tests.ResultsWe compared 246 pre-bundle patients with 203 post-bundle patients. Post-bundle patients experienced a greater proportion of all vital signs collected compared to the pre-intervention cohort (0 % pre-bundle vs. 69 % post-bundle, p < 0.001); specifically, the proportion of respiratory rate (0.8 % pre-bundle vs. 76 % post-bundle, p < 0.001) and temperature (7 % pre-bundle vs. 91 % post-bundle, p < 0.001) vital sign collection significantly increased. The post-bundle cohort had vital signs measured sooner (74 % vital signs measured within 15 min of arrival pre-bundle vs. 90 % post-bundle, p < 0.001) and more frequently per patient (7 % repeated vitals pre-bundle vs 52 % post-bundle, p < 0.001). Key primary survey interventions such as respiratory interventions (1 % pre-bundle vs. 8 % post-bundle, p < 0.001) and cervical collar placement (0 % pre-bundle vs. 7 % post-bundle, p < 0.001) also increased in the post-bundle cohort.ConclusionsThe implementation of a context-appropriate TQI bundle was associated with significant improvements in previously identified trauma care deficits at a single regional hospital. Data-derived interventions targeting frontline capacity at the local level can bridge the gap between identifying care limitations and improvement in resource-limited settings.
- Published
- 2024
10. Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis.
- Author
-
Luijten, Dieuwke, Douillet, Delphine, Luijken, Kim, Tromeur, Cecile, Penaloza, Andrea, Hugli, Olivier, Aujesky, Drahomir, Barco, Stefano, Bledsoe, Joseph, Chang, Kyle, Couturaud, Francis, den Exter, Paul, Font, Carme, Huisman, Menno, Jimenez, David, Kabrhel, Christopher, Kline, Jeffrey, Konstantinides, Stavros, van Mens, Thijs, Otero, Remedios, Peacock, W, Sanchez, Olivier, Stubblefield, William, Valerio, Luca, Vinson, David, Wells, Philip, van Smeden, Maarten, Roy, Pierre-Marie, and Klok, Frederikus
- Subjects
Clinical decision-making ,Early discharge ,Emergency care ,Outpatient care ,Pulmonary embolism ,Humans ,Pulmonary Embolism ,Acute Disease ,Home Care Services ,Hemorrhage ,Male ,Female ,Anticoagulants ,Randomized Controlled Trials as Topic ,Prospective Studies ,Aged ,Natriuretic Peptide ,Brain ,Middle Aged - Abstract
BACKGROUND AND AIMS: Home treatment is considered safe in acute pulmonary embolism (PE) patients selected by a validated triage tool (e.g. simplified PE severity index score or Hestia rule), but there is uncertainty regarding the applicability in underrepresented subgroups. The aim was to evaluate the safety of home treatment by performing an individual patient-level data meta-analysis. METHODS: Ten prospective cohort studies or randomized controlled trials were identified in a systematic search, totalling 2694 PE patients treated at home (discharged within 24 h) and identified by a predefined triage tool. The 14- and 30-day incidences of all-cause mortality and adverse events (combined endpoint of recurrent venous thromboembolism, major bleeding, and/or all-cause mortality) were evaluated. The relative risk (RR) for 14- and 30-day mortalities and adverse events is calculated in subgroups using a random effects model. RESULTS: The 14- and 30-day mortalities were 0.11% [95% confidence interval (CI) 0.0-0.24, I2 = 0) and 0.30% (95% CI 0.09-0.51, I2 = 0). The 14- and 30-day incidences of adverse events were 0.56% (95% CI 0.28-0.84, I2 = 0) and 1.2% (95% CI 0.79-1.6, I2 = 0). Cancer was associated with increased 30-day mortality [RR 4.9; 95% prediction interval (PI) 2.7-9.1; I2 = 0]. Pre-existing cardiopulmonary disease, abnormal troponin, and abnormal (N-terminal pro-)B-type natriuretic peptide [(NT-pro)BNP] at presentation were associated with an increased incidence of 14-day adverse events [RR 3.5 (95% PI 1.5-7.9, I2 = 0), 2.5 (95% PI 1.3-4.9, I2 = 0), and 3.9 (95% PI 1.6-9.8, I2 = 0), respectively], but not mortality. At 30 days, cancer, abnormal troponin, and abnormal (NT-pro)BNP were associated with an increased incidence of adverse events [RR 2.7 (95% PI 1.4-5.2, I2 = 0), 2.9 (95% PI 1.5-5.7, I2 = 0), and 3.3 (95% PI 1.6-7.1, I2 = 0), respectively]. CONCLUSIONS: The incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low. Patients with cancer had a three- to five-fold higher incidence of adverse events and death. Patients with increased troponin or (NT-pro)BNP had a three-fold higher risk of adverse events, driven by recurrent venous thromboembolism and bleeding.
- Published
- 2024
11. Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.
- Author
-
Rubinstein, Arye, Mabudian, Mohsen, McNeil, Donald, Patel, Niraj, Wasserman, Richard, Gupta, Sudhir, Carrasco, Paz, Chen, Jie, Garcia, Enrique, Nagy, Andras, and Yel, Leman
- Subjects
Immunogenicity ,Immunoglobulin replacement ,Inborn errors of immunity ,Quality of life ,Tolerability ,Humans ,Male ,Female ,United States ,Adult ,Adolescent ,Prospective Studies ,Hyaluronoglucosaminidase ,Primary Immunodeficiency Diseases ,Middle Aged ,Infusions ,Subcutaneous ,Child ,Young Adult ,Immunoglobulins ,Injections ,Subcutaneous ,Treatment Outcome ,Aged ,Child ,Preschool ,Immunologic Deficiency Syndromes - Abstract
Facilitated subcutaneous immunoglobulin (fSCIG) 10% is an immunoglobulin replacement therapy that utilizes recombinant human hyaluronidase (rHuPH20) to enhance immunoglobulin dispersion and absorption, allowing for longer treatment intervals similar to intravenous immunoglobulin (up to once monthly). fSCIG 10% is indicated in the USA for treating adults and children aged ≥ 2 years with primary immunodeficiency diseases (PIDs). This prospective, non-interventional, open-label, multicenter, post-authorization safety study (NCT02593188) was conducted in the USA from November 2015 to October 2021 to assess the long-term safety of fSCIG 10% in routine clinical practice. Patients with PIDs aged ≥ 16 years who were prescribed and/or had started fSCIG 10% treatment were enrolled. In total, 253 patients were enrolled and included (full analysis set). Participants received fSCIG 10% treatment for a median (interquartile range) of 10.0 (3.5-11.8) months, with the majority of infusions administered every 4 weeks (54.4% [1197/2201 infusions]) and at home (62.6% [1395/2230 infusions]). Overall, 98.5% of infusions were administered without rate reduction, interruption, or discontinuation due to adverse events (AEs). Treatment-related, non-serious AEs were experienced by 52 patients (20.6%, 284 events). Two patients (0.8%) each experienced one treatment-related serious AE (aseptic meningitis and deep vein thrombosis). Development of antibodies against rHuPH20 was uncommon; 14/196 patients (7.1%) tested positive for binding antibodies (titer ≥ 1:160) with no neutralizing antibodies detected. There was no relationship between anti-rHuPH20 antibody positivity and the occurrence of treatment-related serious or non-serious AEs. Long-term, repeated self-administration of fSCIG 10% was well tolerated in US clinical practice by patients with PIDs.
- Published
- 2024
12. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
- Author
-
Chirenje, Zvavahera, Laher, Fatima, Dintwe, One, Muyoyeta, Monde, deCamp, Allan, He, Zonglin, Grunenberg, Nicole, Laher Omar, Faatima, Seaton, Kelly, Polakowski, Laura, Woodward Davis, Amanda, Maganga, Lucas, Baden, Lindsey, Mayer, Kenneth, Kalams, Spyros, Keefer, Michael, Edupuganti, Srilatha, Rodriguez, Benigno, Frank, Ian, Scott, Hyman, Stranix-Chibanda, Lynda, Gurunathan, Sanjay, Koutsoukos, Marguerite, Van Der Meeren, Olivier, DiazGranados, Carlos, Paez, Carmen, Andersen-Nissen, Erica, Kublin, James, Corey, Lawrence, Ferrari, Guido, Tomaras, Georgia, and McElrath, M
- Subjects
HIV ,adjuvant ,dose ,vaccine ,Humans ,Female ,Adjuvants ,Immunologic ,AIDS Vaccines ,Adult ,Male ,Young Adult ,HIV Infections ,HIV Envelope Protein gp120 ,Adolescent ,Double-Blind Method ,HIV Antibodies ,Squalene ,Polysorbates ,HIV-1 ,Viral Vaccines - Abstract
BACKGROUND: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at 2 dose levels in healthy HIV-uninfected adults. METHODS: Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B. Primary outcomes were safety and immune responses. RESULTS: We enrolled 160 participants, 55% women, 18-40 years old (median age 24 years) of whom 150 received vaccine and 10 placebo. Vaccines were generally safe and well tolerated. At months 6.5 and 12, CD4+ T-cell response rates and magnitudes were higher in the AS01B-adjuvanted groups than in the MF59-adjuvanted group. At month 12, HIV-specific Env-gp120 binding antibody response magnitudes in the 40 μg gp120/AS01B group were higher than in either of the 200 μg gp120 groups. CONCLUSIONS: The 40 μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses. Clinical Trials Registration . NCT03122223.
- Published
- 2024
13. Exploring the effect of sedentary behavior on increased adiposity in middle-aged adults.
- Author
-
Macías, Nayeli, Monterrubio-Flores, Eric, Salmerón, Jorge, Meneses-León, Joacim, Flores, Yvonne, Jáuregui, Alejandra, Salvo, Deborah, Villa, Umberto, Olvera, Armando, and Gallegos-Carrillo, Katia
- Subjects
Body fat ,Cohort study ,Middle-aged adults ,Sedentary behavior ,Self-report correction ,Humans ,Sedentary Behavior ,Male ,Female ,Middle Aged ,Adult ,Adiposity ,Accelerometry ,Cohort Studies ,Absorptiometry ,Photon ,Self Report ,Surveys and Questionnaires - Abstract
BACKGROUND: Sedentary behavior is linked to excess fat mass; however, this association may be inconclusive due to potential measurement errors in self-reported sedentary behavior. OBJECTIVE: To assess the association between changes in sedentary behavior and fat mass in a Cohort of Health Workers (HWCS) from 2004 to 2010. METHODS: A total of 1,285 adults participating in the Cohort of Health Workers were evaluated in 2004 and 2010. Fat mass (kg) was measured by dual X-ray absorptiometry. A self-administered questionnaire was used to estimate the sedentary behavior. Sedentary behavior was also estimated using accelerometry in a sample of 142 health workers. Accelerometry data were used to correct self-reported sedentary behavior using a generalized linear model, which included values for sleeping time, age, sex, sedentary behavior, glucose, and triglycerides. Concordance between both methods was assessed using a kappa and Bland-Altman analysis. Once sedentary behavior was corrected, the values were used to evaluate the association between changes in sedentary behavior and body fat mass using a fixed effect model in the cohort, adjusting for confounders. RESULTS: Self-reported sedentary behavior was 2.8 ± 1.8 and 2.3 ± 1.6 h/day, and body fat mass was 24.9 ± 8.1 and 26.8 ± 8.5 kg in 2004 and 2010, respectively. After applying the correction model, the self-reported sedentary behavior was 7.6 ± 1.2 and 7.5 ± 1.2 h/day in 2004 and 2010, respectively. For every hour increase in corrected sedentary behavior, there was an observed increase of 0.847 (p > 0.001) kg in body fat mass during the 6.8 years in the Cohort of Health Workers from 2004 to 2010. Conversely, non-corrected self-reported sedentary behavior was associated with a non-significant reduction of 0.097 kg (p = 0.228) for every hour of sedentary behavior. CONCLUSIONS: Increased sedentary behavior was associated with increased body fat mass when corrected self-reported sedentary behavior was used. Implementing public health strategies to reduce sedentary behavior is imperative.
- Published
- 2024
14. Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers
- Author
-
Ellison, Gary L, Helzlsouer, Kathy J, Rosenfield, Sonia M, Kim, Yun, Ashare, Rebecca L, Blaes, Anne H, Cullen, Jennifer, Doran, Neal, Ebbert, Jon O, Egan, Kathleen M, Heffner, Jaimee L, Lee, Richard T, McClure, Erin A, McDaniels-Davidson, Corinne, Meghani, Salimah H, Newcomb, Polly A, Nugent, Shannon, Hernandez-Ortega, Nicholas, Salz, Talya, Vidot, Denise C, Worster, Brooke, and Zylla, Dylan M
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Behavioral and Social Science ,Women's Health ,Cancer ,Clinical Research ,Cannabinoid Research ,Social Determinants of Health ,7.1 Individual care needs ,Humans ,Neoplasms ,Female ,Male ,United States ,Middle Aged ,Prevalence ,Adult ,Medical Marijuana ,National Cancer Institute (U.S.) ,Surveys and Questionnaires ,Cancer Care Facilities ,Aged ,Perception ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundThe legal climate for cannabis use has dramatically changed with an increasing number of states passing legislation legalizing access for medical and recreational use. Among cancer patients, cannabis is often used to ameliorate adverse effects of cancer treatment. Data are limited on the extent and type of use among cancer patients during treatment and the perceived benefits and harms. This multicenter survey was conducted to assess the use of cannabis among cancer patients residing in states with varied legal access to cannabis.MethodsA total of 12 NCI-Designated Cancer Centers, across states with varied cannabis-access legal status, conducted surveys with a core questionnaire to assess cannabis use among recently diagnosed cancer patients. Data were collected between September 2021 and August 2023 and pooled across 12 cancer centers. Frequencies and 95% confidence intervals for core survey measures were calculated, and weighted estimates are presented for the 10 sites that drew probability samples.ResultsOverall reported cannabis use since cancer diagnosis among survey respondents was 32.9% (weighted), which varied slightly by state legalization status. The most common perceived benefits of use were for pain, sleep, stress and anxiety, and treatment side effects. Reported perceived risks were less common and included inability to drive, difficulty concentrating, lung damage, addiction, and impact on employment. A majority reported feeling comfortable speaking to health-care providers though, overall, only 21.5% reported having done so. Among those who used cannabis since diagnosis, the most common modes were eating in food, smoking, and pills or tinctures, and the most common reasons were for sleep disturbance, followed by pain and stress and anxiety with 60%-68% reporting improved symptoms with use.ConclusionThis geographically diverse survey demonstrates that patients use cannabis regardless of its legal status. Addressing knowledge gaps concerning benefits and harms of cannabis use during cancer treatment is critical to enhance patient-provider communication.
- Published
- 2024
15. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
- Author
-
Saner, Flurina, Takahashi, Kazuaki, Budden, Timothy, Pandey, Ahwan, Ariyaratne, Dinuka, Zwimpfer, Tibor, Meagher, Nicola, Fereday, Sian, Twomey, Laura, Pishas, Kathleen, Hoang, Therese, Bolithon, Adelyn, Traficante, Nadia, Alsop, Kathryn, Christie, Elizabeth, Kang, Eun-Young, Nelson, Gregg, Ghatage, Prafull, Lee, Cheng-Han, Riggan, Marjorie, Alsop, Jennifer, Beckmann, Matthias, Boros, Jessica, Brand, Alison, Brooks-Wilson, Angela, Carney, Michael, Coulson, Penny, Courtney-Brooks, Madeleine, Cushing-Haugen, Kara, Cybulski, Cezary, El-Bahrawy, Mona, Elishaev, Esther, Erber, Ramona, Gayther, Simon, Gentry-Maharaj, Aleksandra, Gilks, C, Harnett, Paul, Harris, Holly, Hartmann, Arndt, Hein, Alexander, Hendley, Joy, Hernandez, Brenda, Jakubowska, Anna, Jimenez-Linan, Mercedes, Jones, Michael, Kaufmann, Scott, Kennedy, Catherine, Kluz, Tomasz, Koziak, Jennifer, Kristjansdottir, Björg, Le, Nhu, Lener, Marcin, Lester, Jenny, Lubiński, Jan, Mateoiu, Constantina, Orsulic, Sandra, Ruebner, Matthias, Schoemaker, Minouk, Shah, Mitul, Sharma, Raghwa, Sherman, Mark, Shvetsov, Yurii, Soong, T, Steed, Helen, Sukumvanich, Paniti, Talhouk, Aline, Taylor, Sarah, Vierkant, Robert, Wang, Chen, Widschwendter, Martin, Wilkens, Lynne, Winham, Stacey, Anglesio, Michael, Berchuck, Andrew, Brenton, James, Campbell, Ian, Cook, Linda, Doherty, Jennifer, Fasching, Peter, Fortner, Renée, Goodman, Marc, Gronwald, Jacek, Karlan, Beth, Kelemen, Linda, Menon, Usha, Modugno, Francesmary, Pharoah, Paul, Schildkraut, Joellen, Sundfeldt, Karin, Swerdlow, Anthony, Goode, Ellen, DeFazio, Anna, Köbel, Martin, Ramus, Susan, Bowtell, David, and Garsed, Dale
- Subjects
Humans ,Female ,Ovarian Neoplasms ,BRCA2 Protein ,BRCA1 Protein ,Cystadenocarcinoma ,Serous ,Retinoblastoma Binding Proteins ,Prognosis ,Ubiquitin-Protein Ligases ,Neoplasm Grading ,Lymphocytes ,Tumor-Infiltrating ,Middle Aged ,Germ-Line Mutation ,Gene Expression Regulation ,Neoplastic ,Aged ,Biomarkers ,Tumor ,CD8-Positive T-Lymphocytes - Abstract
PURPOSE: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences survival in tubo-ovarian high-grade serous carcinoma (HGSC). EXPERIMENTAL DESIGN: RB1 protein expression was classified by immunohistochemistry in ovarian carcinomas of 7,436 patients from the Ovarian Tumor Tissue Analysis consortium. We examined RB1 expression and germline BRCA status in a subset of 1,134 HGSC, and related genotype to overall survival (OS), tumor-infiltrating CD8+ lymphocytes, and transcriptomic subtypes. Using CRISPR-Cas9, we deleted RB1 in HGSC cells with and without BRCA1 alterations to model co-loss with treatment response. We performed whole-genome and transcriptome data analyses on 126 patients with primary HGSC to characterize tumors with concurrent BRCA deficiency and RB1 loss. RESULTS: RB1 loss was associated with longer OS in HGSC but with poorer prognosis in endometrioid ovarian carcinoma. Patients with HGSC harboring both RB1 loss and pathogenic germline BRCA variants had superior OS compared with patients with either alteration alone, and their median OS was three times longer than those without pathogenic BRCA variants and retained RB1 expression (9.3 vs. 3.1 years). Enhanced sensitivity to cisplatin and paclitaxel was seen in BRCA1-altered cells with RB1 knockout. Combined RB1 loss and BRCA deficiency correlated with transcriptional markers of enhanced IFN response, cell-cycle deregulation, and reduced epithelial-mesenchymal transition. CD8+ lymphocytes were most prevalent in BRCA-deficient HGSC with co-loss of RB1. CONCLUSIONS: Co-occurrence of RB1 loss and BRCA deficiency was associated with exceptionally long survival in patients with HGSC, potentially due to better treatment response and immune stimulation.
- Published
- 2024
16. Non-injection drug use among incarcerated people in Iran: Findings from three consecutive national bio-behavioral surveys.
- Author
-
Rafiee, Mahkameh, Karamouzian, Mohammad, Sharifi, Mohammad, Mirzazadeh, Ali, Khezri, Mehrdad, Haghdoost, Ali, Mehmandoost, Soheil, and Sharifi, Hamid
- Subjects
Harm reduction ,Iran ,Prisons ,Substance-related disorders ,Humans ,Iran ,Male ,Adult ,Female ,Prisoners ,Substance-Related Disorders ,Young Adult ,Middle Aged ,Prevalence ,Prisons ,Adolescent ,Risk Factors ,Cross-Sectional Studies - Abstract
BACKGROUND: Prisons often serve as high-risk environments for drug use, and incarcerated people are at a high risk for substance use-related mental and physical harms. This study aimed to determine the prevalence of non-injection drug use inside the prison and its related factors among incarcerated people in Iran. METHODS: We utilized data from three national bio-behavioral surveillance surveys conducted among incarcerated people in Iran in 2009, 2013, and 2017. Eligibility criteria were being ≥ 18 years old, providing informed consent, and being incarcerated for over a week. Overall, 17,228 participants across all surveys were recruited through a multi-stage random sampling approach. Each participant underwent a face-to-face interview and HIV test. The primary objective of the study was to assess self-reported non-injection drug use within the prison environment within the last month. A multivariable logistic regression model was built to determine associated covariates with drug use inside prison and an adjusted odds ratio (aOR) with 95% confidence intervals (CI) were reported. RESULT: The prevalence of non-injection drug use inside the prison was 24.1% (95% CI 23.5, 24.7) with a significant decreasing trend (39.7% in 2009, 17.8% in 2013, 14.0% in 2017; p-value
- Published
- 2024
17. Dimensions of wisdom perception across twelve countries on five continents.
- Author
-
Rudnev, M, Barrett, Harold, Buckwalter, W, Machery, E, Stich, S, Barr, K, Bencherifa, A, Clancy, R, Crone, D, Deguchi, Y, Fabiano, E, Fodeman, A, Guennoun, B, Halamová, J, Hashimoto, T, Homan, J, Kanovský, M, Karasawa, K, Kim, H, Kiper, J, Lee, M, Liu, X, Mitova, V, Nair, R, Pantovic, L, Porter, B, Quintanilla, P, Reijer, J, Romero, P, Singh, P, Tber, S, Wilkenfeld, D, Yi, L, and Grossmann, I
- Subjects
Humans ,Female ,Male ,Adult ,Judgment ,Young Adult ,Emotions ,Knowledge ,Cross-Cultural Comparison ,Cognition ,Middle Aged ,Social Perception ,Adolescent ,Perception - Abstract
Wisdom is the hallmark of social judgment, but how people across cultures recognize wisdom remains unclear-distinct philosophical traditions suggest different views of wisdoms cardinal features. We explore perception of wise minds across 16 socio-economically and culturally diverse convenience samples from 12 countries. Participants assessed wisdom exemplars, non-exemplars, and themselves on 19 socio-cognitive characteristics, subsequently rating targets wisdom, knowledge, and understanding. Analyses reveal two positively related dimensions-Reflective Orientation and Socio-Emotional Awareness. These dimensions are consistent across the studied cultural regions and interact when informing wisdom ratings: wisest targets-as perceived by participants-score high on both dimensions, whereas the least wise are not reflective but moderately socio-emotional. Additionally, individuals view themselves as less reflective but more socio-emotionally aware than most wisdom exemplars. Our findings expand folk psychology and social judgment research beyond the Global North, showing how individuals perceive desirable cognitive and socio-emotional qualities, and contribute to an understanding of mind perception.
- Published
- 2024
18. Associations between gut microbiota and incident fractures in the FINRISK cohort.
- Author
-
Grahnemo, Louise, Kambur, Oleg, Lahti, Leo, Jousilahti, Pekka, Niiranen, Teemu, Knight, Rob, Salomaa, Veikko, Havulinna, Aki, and Ohlsson, Claes
- Subjects
Gastrointestinal Microbiome ,Humans ,Male ,Female ,Fractures ,Bone ,Middle Aged ,Finland ,Aged ,Bacteria ,Metagenome ,Cohort Studies ,Incidence ,Metagenomics ,Proteobacteria ,Risk Factors ,Adult - Abstract
The gut microbiota (GM) can regulate bone mass, but its association with incident fractures is unknown. We used Cox regression models to determine whether the GM composition is associated with incident fractures in the large FINRISK 2002 cohort (n = 7043, 1092 incident fracture cases, median follow-up time 18 years) with information on GM composition and functionality from shotgun metagenome sequencing. Higher alpha diversity was associated with decreased fracture risk (hazard ratio [HR] 0.92 per standard deviation increase in Shannon index, 95% confidence interval 0.87-0.96). For beta diversity, the first principal component was associated with fracture risk (Aitchison distance, HR 0.90, 0.85-0.96). In predefined phyla analyses, we observed that the relative abundance of Proteobacteria was associated with increased fracture risk (HR 1.14, 1.07-1.20), while the relative abundance of Tenericutes was associated with decreased fracture risk (HR 0.90, 0.85-0.96). Explorative sub-analyses within the Proteobacteria phylum showed that higher relative abundance of Gammaproteobacteria was associated with increased fracture risk. Functionality analyses showed that pathways related to amino acid metabolism and lipopolysaccharide biosynthesis associated with fracture risk. The relative abundance of Proteobacteria correlated with pathways for amino acid metabolism, while the relative abundance of Tenericutes correlated with pathways for butyrate synthesis. In conclusion, the overall GM composition was associated with incident fractures. The relative abundance of Proteobacteria, especially Gammaproteobacteria, was associated with increased fracture risk, while the relative abundance of Tenericutes was associated with decreased fracture risk. Functionality analyses demonstrated that pathways known to regulate bone health may underlie these associations.
- Published
- 2024
19. Exploring the acceptability, barriers, and facilitators to psychosis screening in the integrated behavioral health primary care setting: a qualitative study.
- Author
-
Savill, Mark, Loewy, Rachel, Gobrial, Sarah, Kirkpatrick, Julianna, Porteus, A, Lesh, Tyler, Ragland, J, Niendam, Tara, and Carter, Cameron
- Subjects
Clinical high-risk syndrome ,Pathways to care ,Primary care ,Prodromal questionnaire – brief ,Qualitative interviews ,Schizophrenia ,Screening ,Humans ,Primary Health Care ,Psychotic Disorders ,Qualitative Research ,Male ,Female ,Adult ,Mass Screening ,Patient Acceptance of Health Care ,Interviews as Topic ,Middle Aged ,Delivery of Health Care ,Integrated ,Mental Health Services ,Attitude of Health Personnel - Abstract
BACKGROUND: A longer duration of untreated psychosis (DUP) is associated with poorer treatment outcomes. Screening for psychosis spectrum disorders in the primary care setting could help support the earlier detection and treatment of individuals in need. However, the acceptability of screening for psychosis in this setting as part of routine care is currently unknown. METHODS: We conducted a qualitative interview study with providers and service users who participated in an early psychosis screening program conducted in an integrated behavioral health primary care (IBH-PC) setting. Interviews were recruited from one of eight WellSpace Federally Qualified Health Center IBH-PC clinics in the Sacramento, CA area. Transcripts of the recorded interviews were analyzed using thematic analysis. RESULTS: In total, 12 providers and eight service users participated in the interviews. Most service user and provider participants were supportive of psychosis screening in an IBH-PC setting, but not as part of the general practitioner consultation due to the brief, non-behavioral health nature of many of the appointments, and the expected low prevalence of psychosis in this population. The support of leadership, adequate training and support, staff turnover, and organizational changes were all seen to impact the successful implementation of the program. Different barriers and facilitators were considered important at each stage of the process from introducing the screening procedures to service users; to determining when, where, and how to screen; and how to effectively manage the referral and post-referral stages. CONCLUSIONS: Despite the additional challenges of screening in an IBH-PC setting relative to secondary mental health services, the process was considered acceptable and feasible to providers and service users. Services that plan to conduct psychosis screening in their clinics need to consider the challenges and their potential solutions to implementation at each stage of the screening process.
- Published
- 2024
20. Urinary polycyclic aromatic hydrocarbon metabolites and their association with oxidative stress among pregnant women in Los Angeles.
- Author
-
Meng, Qi, Mitra, Sanjali, Del Rosario, Irish, Jerrett, Michael, Janzen, Carla, Devaskar, Sherin, and Ritz, Beate
- Subjects
Oxidative stress ,PAH (polycyclic aromatic hydrocarbons) ,Pregnancy ,Humans ,Female ,Polycyclic Aromatic Hydrocarbons ,Los Angeles ,Pregnancy ,Oxidative Stress ,Adult ,Biomarkers ,Young Adult ,Environmental Pollutants ,8-Hydroxy-2-Deoxyguanosine ,Cohort Studies ,Maternal Exposure ,Malondialdehyde - Abstract
BACKGROUND: Polycyclic aromatic hydrocarbons (PAHs) have been linked to adverse birth outcomes that have been reported to be induced by oxidative stress, but few epidemiological studies to date have evaluated associations between urinary PAH metabolites and oxidative stress biomarkers in pregnancy and identified critical periods for these outcomes and PAH exposures in pregnancy. METHODS: A cohort of pregnant women was recruited early in pregnancy from antenatal clinics at the University of California Los Angeles during 2016-2019. We collected urine samples up to three times during pregnancy in a total of 159 women enrolled in the cohort. A total of 7 PAH metabolites and 2 oxidative stress biomarkers [malondialdehyde (MDA), 8-hydroxy-2-deoxyguanosine (8-OHdG)] were measured in all available urine samples. Using multiple linear regression models, we estimated the percentage change (%) and 95% confidence interval (CI) in 8-OHdG and MDA measured at each sample collection time per doubling of PAH metabolite concentrations. Furthermore, we used linear mixed models with a random intercept for participant to estimate the associations between PAH metabolite and oxidative stress biomarker concentrations across multiple time points in pregnancy. RESULTS: Most PAH metabolites were positively associated with both urinary oxidative stress biomarkers, MDA and 8-OHdG, with stronger associations in early and late pregnancy. A doubling of each urinary PAH metabolite concentration increased MDA concentrations by 5.8-41.1% and 8-OHdG concentrations by 13.8-49.7%. Linear mixed model results were consistent with those from linear regression models for each gestational sampling period. CONCLUSION: Urinary PAH metabolites are associated with increases in oxidative stress biomarkers during pregnancy, especially in early and late pregnancy.
- Published
- 2024
21. Genomic profiles and clinical presentation of chordoma.
- Author
-
Koka, Hela, Zhou, Weiyin, McMaster, Mary, Bai, Jiwei, Luo, Wen, Klein, Alyssa, Zhang, Tongwu, Hua, Xing, Li, Xin, Wang, Difei, Xiong, Yujia, Jones, Kristine, Vogt, Aurelie, Hicks, Belynda, Parry, Dilys, Goldstein, Allen, and Yang, Xiaohong
- Subjects
Chordoma ,Chordoma sites ,Clinical outcome ,Genomic landscape ,Treatment ,Humans ,Chordoma ,Male ,Female ,Middle Aged ,Aged ,Adult ,Adolescent ,Young Adult ,Child ,Child ,Preschool ,DNA-Binding Proteins ,Mutation ,Class I Phosphatidylinositol 3-Kinases ,T-Box Domain Proteins ,Transcription Factors ,Nuclear Proteins ,Skull Base Neoplasms ,Spinal Neoplasms ,Canada ,Polymorphism ,Single Nucleotide ,Fetal Proteins ,Histone-Lysine N-Methyltransferase - Abstract
Chordoma is a rare bone cancer with variable clinical outcomes. Here, we recruited 184 sporadic chordoma patients from the US and Canada and collected their clinical and treatment data. The average age at diagnosis was 45.5 years (Range 5-78) and the chordoma site distribution was 49.2% clivus, 26.2% spinal, and 24.0% sacral. Most patients (97.5%) received surgery as the primary treatment, among whom 85.3% also received additional treatment. Except for the most prevalent cancers like prostate, lung, breast, and skin cancer, there was no discernible enrichment for any specific cancer type among patients or their family members. Among a subset of patients (N = 70) with tumor materials, we conducted omics analyses and obtained targeted panel sequencing and SNP array genotyping data for 51 and 49 patients, respectively. The most recurrent somatic driver mutations included PIK3CA (12%), followed by chromatin remodeling genes PBRM1 and SETD2. Amplification of the 6q27 region, containing the chordoma susceptibility gene TBXT, was detected in eight patients (16.3%). Clival patients appeared to be less likely to carry driver gene mutations, chromosome arm level deletion events (e.g., 5p, 5p, and 9p), or 6q27 amplification compared to sacral patients. After adjusting for age, sex, tumor site, and additional treatment, patients with somatic deletions of 14q (OR = 13.73, 95% CI 1.96-96.02, P = 0.008) and 18p (OR = 13.68, 95% CI 1.77-105.89, P = 0.012) were more likely to have persistent chordoma. The study highlights genomic heterogeneity in chordoma, potentially linked to location and clinical progression.
- Published
- 2024
22. Sustained mucosal colonization and fecal metabolic dysfunction by Bacteroides associates with fecal microbial transplant failure in ulcerative colitis patients.
- Author
-
Zhang, Bing, Magnaye, Kevin, Stryker, Emily, Moltzau-Anderson, Jacqueline, Porsche, Cara, Hertz, Sandra, McCauley, Kathryn, Smith, Byron, Zydek, Martin, Pollard, Katherine, Ma, Averil, El-Nachef, Najwa, and Lynch, Susan
- Subjects
Humans ,Colitis ,Ulcerative ,Fecal Microbiota Transplantation ,Male ,Female ,Feces ,Bacteroides ,Adult ,Intestinal Mucosa ,Middle Aged ,Gastrointestinal Microbiome ,Treatment Failure ,RNA ,Ribosomal ,16S ,Metabolome - Abstract
Fecal microbial transplantation (FMT) offers promise for treating ulcerative colitis (UC), though the mechanisms underlying treatment failure are unknown. This study harnessed longitudinally collected colonic biopsies (n = 38) and fecal samples (n = 179) from 19 adults with mild-to-moderate UC undergoing serial FMT in which antimicrobial pre-treatment and delivery mode (capsules versus enema) were assessed for clinical response (≥ 3 points decrease from the pre-treatment Mayo score). Colonic biopsies underwent dual RNA-Seq; fecal samples underwent parallel 16S rRNA and shotgun metagenomic sequencing as well as untargeted metabolomic analyses. Pre-FMT, the colonic mucosa of non-responsive (NR) patients harbored an increased burden of bacteria, including Bacteroides, that expressed more antimicrobial resistance genes compared to responsive (R) patients. NR patients also exhibited muted mucosal expression of innate immune antimicrobial response genes. Post-FMT, NR and R fecal microbiomes and metabolomes exhibited significant divergence. NR metabolomes had elevated concentrations of immunostimulatory compounds including sphingomyelins, lysophospholipids and taurine. NR fecal microbiomes were enriched for Bacteroides fragilis and Bacteroides salyersiae strains that encoded genes capable of taurine production. These findings suggest that both effective mucosal microbial clearance and reintroduction of bacteria that reshape luminal metabolism associate with FMT success and that persistent mucosal and fecal colonization by antimicrobial-resistant Bacteroides species may contribute to FMT failure.
- Published
- 2024
23. A maternal brain hormone that builds bone
- Author
-
Babey, Muriel E, Krause, William C, Chen, Kun, Herber, Candice B, Torok, Zsofia, Nikkanen, Joni, Rodriguez, Ruben, Zhang, Xiao, Castro-Navarro, Fernanda, Wang, Yuting, Wheeler, Erika E, Villeda, Saul, Leach, J Kent, Lane, Nancy E, Scheller, Erica L, Chan, Charles KF, Ambrosi, Thomas H, and Ingraham, Holly A
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Nutrition ,Women's Health ,Regenerative Medicine ,Neurosciences ,Breastfeeding ,Lactation and Breast Milk ,Stem Cell Research ,Stem Cell Research - Nonembryonic - Non-Human ,1.1 Normal biological development and functioning ,Animals ,Female ,Mice ,Lactation ,Male ,Humans ,Neurons ,Arcuate Nucleus of Hypothalamus ,Osteogenesis ,Bone Remodeling ,Stem Cells ,Bone and Bones ,Calcium ,Bone Resorption ,Mice ,Inbred C57BL ,Bone Density ,Brain ,Hormones ,Mothers ,Aging ,Adolescent ,Nephroblastoma Overexpressed Protein ,General Science & Technology - Abstract
In lactating mothers, the high calcium (Ca2+) demand for milk production triggers significant bone loss1. Although oestrogen normally counteracts excessive bone resorption by promoting bone formation, this sex steroid drops precipitously during this postpartum period. Here we report that brain-derived cellular communication network factor 3 (CCN3) secreted from KISS1 neurons of the arcuate nucleus (ARCKISS1) fills this void and functions as a potent osteoanabolic factor to build bone in lactating females. We began by showing that our previously reported female-specific, dense bone phenotype2 originates from a humoral factor that promotes bone mass and acts on skeletal stem cells to increase their frequency and osteochondrogenic potential. This circulatory factor was then identified as CCN3, a brain-derived hormone from ARCKISS1 neurons that is able to stimulate mouse and human skeletal stem cell activity, increase bone remodelling and accelerate fracture repair in young and old mice of both sexes. The role of CCN3 in normal female physiology was revealed after detecting a burst of CCN3 expression in ARCKISS1 neurons coincident with lactation. After reducing CCN3 in ARCKISS1 neurons, lactating mothers lost bone and failed to sustain their progeny when challenged with a low-calcium diet. Our findings establish CCN3 as a potentially new therapeutic osteoanabolic hormone for both sexes and define a new maternal brain hormone for ensuring species survival in mammals.
- Published
- 2024
24. Associations of luteal phase changes in vagally mediated heart rate variability with premenstrual emotional changes.
- Author
-
Schmalenberger, Katja, Eisenlohr-Moul, Tory, Jarczok, Marc, Schneider, Ekaterina, Barone, Jordan, Thayer, Julian, and Ditzen, Beate
- Subjects
Menstrual cycle ,Negative affect ,Progesterone ,Vagally mediated heart rate variability ,Humans ,Female ,Luteal Phase ,Heart Rate ,Adult ,Progesterone ,Emotions ,Affect ,Vagus Nerve ,Young Adult ,Premenstrual Syndrome - Abstract
BACKGROUND: A recent meta-analysis revealed that vagally mediated heart rate variability (vmHRV; a biomarker of emotion regulation capacity) significantly decreases in the luteal phase of the menstrual cycle. As two follow-up studies suggest, these vmHRV decreases are driven primarily by increased luteal progesterone (P4). However, analyses also revealed significant interindividual differences in vmHRV reactivity to the cycle, which is in line with longstanding evidence for interindividual differences in mood sensitivity to the cycle. The present study begins to investigate whether these interindividual differences in vmHRV cyclicity can explain who is at higher risk of showing premenstrual emotional changes. We expected a greater degree of midluteal vmHRV decrease to be predictive of a greater premenstrual increase in negative affect. METHODS: We conducted an observational study with a naturally cycling community sample (N = 31, M = 26.03 years). Over a span of six weeks, participants completed (a) daily ratings of negative affect and (b) counterbalanced lab visits in their ovulatory, midluteal, and perimenstrual phases. Lab visits were scheduled based on positive ovulation tests and included assessments of baseline vmHRV and salivary ovarian steroid levels. RESULTS: In line with previous research, multilevel models suggest that most of the sample shows ovulatory-to-midluteal vmHRV decreases which, however, were not associated with premenstrual emotional changes. Interestingly, it was only the subgroup with luteal increases in vmHRV whose negative affect markedly worsened premenstrually and improved postmenstrually. CONCLUSION: The present study begins to investigate cyclical changes in vmHRV as a potential biomarker of mood sensitivity to the menstrual cycle. The results demonstrate a higher level of complexity in these associations than initially expected, given that only atypical midluteal increases in vmHRV are associated with greater premenstrual negative affect. Potential underlying mechanisms are discussed, among those the possibility that luteal vmHRV increases index compensatory efforts to regulate emotion in those with greater premenstrual negative affect. However, future studies with larger and clinical samples and more granular vmHRV assessments should build on these findings and further explore associations between vmHRV cyclicity and menstrually related mood changes.
- Published
- 2024
25. Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence.
- Author
-
Martinez-Lopez, J, Lopez-Muñoz, N, Chari, A, Dorado, S, Barrio, S, Arora, S, Kumar, A, Chung, A, Martin, T, and Wolf, J
- Subjects
Humans ,Multiple Myeloma ,Neoplasm ,Residual ,Male ,Female ,Middle Aged ,Aged ,Artificial Intelligence ,Retrospective Studies ,Adult ,Aged ,80 and over - Abstract
Minimal residual disease (MRD) assessment is a known surrogate marker for survival in multiple myeloma (MM). Here, we present a single institutions experience assessing MRD by NGS of Ig genes and the long-term impact of depth of response as well as clonal diversity on the clinical outcome of a large population of MM patients; 482 MM patients at the University of California, San Francisco (UCSF) diagnosed from 2008 to 2020 were analyzed retrospectively. MRD assessment was performed by NGS. PFS curves were plotted by the Kaplan-Meier method. In the newly diagnosed group, 119 of 304, achieved MRD negativity at the level of 10-6 at least once. These patients had a prolonged PFS versus patients who were persistently MRD positive at different levels (p > 0.0001). In the relapsed disease group, 64 of 178 achieved MRD negativity at 10-6, and PFS was prolonged versus patients who remained MRD positive (p = 0.03). Three categories of MRD dynamics were defined by artificial intelligence: (A) patients with ≥3 consistently MRD negative samples, (B) patients with continuously declining but detectable clones, and (C) patients with either increasing or a stable number of clones. Groups A and B had a more prolonged PFS than group C (p
- Published
- 2024
26. Estimating the Seroincidence of Scrub Typhus using Antibody Dynamics after Infection
- Author
-
Aiemjoy, Kristen, Katuwal, Nishan, Vaidya, Krista, Shrestha, Sony, Thapa, Melina, Teunis, Peter, Bogoch, Isaac I, Trowbridge, Paul, Blacksell, Stuart D, Paris, Daniel H, Wangrangsimakul, Tri, Varghese, George M, Maude, Richard J, Tamrakar, Dipesh, and Andrews, Jason R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Vector-Borne Diseases ,Infectious Diseases ,Clinical Research ,Prevention ,Infection ,Good Health and Well Being ,Scrub Typhus ,Humans ,India ,Seroepidemiologic Studies ,Nepal ,Immunoglobulin G ,Antibodies ,Bacterial ,Orientia tsutsugamushi ,Immunoglobulin M ,Incidence ,Adult ,Male ,Female ,Thailand ,Adolescent ,Young Adult ,Bayes Theorem ,Middle Aged ,Medical and Health Sciences ,Tropical Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
Scrub typhus, a vector-borne bacterial infection, is an important but neglected disease globally. Accurately characterizing the burden is challenging because of nonspecific symptoms and limited diagnostics. Prior seroepidemiology studies have struggled to find consensus cutoffs that permit comparisons of estimates across contexts and time. In this study, we present a novel approach that does not require a cutoff and instead uses information about antibody kinetics after infection to estimate seroincidence. We use data from three cohorts of scrub typhus patients in Chiang Rai, Thailand, and Vellore, India, to characterize antibody kinetics after infection and two population serosurveys in the Kathmandu Valley, Nepal, and Tamil Nadu, India, to estimate seroincidence. The samples were tested for IgM and IgG responses to Orientia tsutsugamushi-derived recombinant 56-kDa antigen using commercial enzyme-linked immunosorbent assay kits. We used Bayesian hierarchical models to characterize antibody responses after scrub typhus infection and used the joint distributions of the peak antibody titers and decay rates to estimate population-level incidence rates in the cross-sectional serosurveys. Median responses persisted above an optical density (OD) of 1.8 for 23.6 months for IgG and an OD of 1 for 4.5 months for IgM. Among 18- to 29-year-olds, the seroincidence was 10 per 1,000 person-years (95% CI, 5-19) in Tamil Nadu, India, and 14 per 1,000 person-years (95% CI: 10-20) in the Kathmandu Valley, Nepal. When seroincidence was calculated with antibody decay ignored, the disease burden was underestimated by more than 50%. The approach can be deployed prospectively, coupled with existing serosurveys, or leverage banked samples to efficiently generate scrub typhus seroincidence estimates.
- Published
- 2024
27. Vaginal fungi are associated with treatment-induced shifts in the vaginal microbiota and with a distinct genital immune profile.
- Author
-
Armstrong, Eric, Hemmerling, Anke, Miller, Steve, Huibner, Sanja, Kulikova, Maria, Liu, Rachel, Crawford, Emily, Castañeda, Gloria, Coburn, Bryan, Cohen, Craig, and Kaul, Rupert
- Subjects
Candida ,fungi ,genital immunology ,inflammation ,vaginal microbiome ,Female ,Humans ,Vagina ,Vaginosis ,Bacterial ,Metronidazole ,Microbiota ,Adult ,Candida albicans ,Lactobacillus crispatus ,Interleukin-17 ,Young Adult ,Fungi ,Lactobacillus ,Cytokines ,Probiotics ,Bacteria - Abstract
Vaginal colonization by fungi may elicit genital inflammation and enhance the risk of adverse reproductive health outcomes, such as HIV acquisition. Cross-sectional studies have linked fungi with an absence of bacterial vaginosis (BV), but it is unclear whether shifts in vaginal bacteria alter the abundance of vaginal fungi. Vaginal swabs collected following topical metronidazole treatment for BV during the phase 2b, placebo-controlled trial of LACTIN-V, a Lactobacillus crispatus-based live biotherapeutic, were assayed with semi-quantitative PCR for the relative quantitation of fungi and key bacterial species and multiplex immunoassay for immune factors. Vaginal fungi increased immediately following metronidazole treatment for BV (adjusted P = 0.0006), with most of this increase attributable to Candida albicans. Vaginal fungi were independently linked to elevated levels of the proinflammatory cytokine interleukin (IL) 17A, although this association did not remain significant after correcting for multiple comparisons. Fungal relative abundance by semi-quantitative PCR returned to baseline levels within 1 month of metronidazole treatment and was not affected by LACTIN-V or placebo administration. Fungal abundance was positively associated with Lactobacillus species, negatively associated with BV-associated bacteria, and positively associated with a variety of proinflammatory cytokines and chemokines, including IL-17A, during and after study product administration. Antibiotic treatment for BV resulted in a transient expanded abundance of vaginal fungi in a subset of women which was unaffected by subsequent administration of LACTIN-V. Vaginal fungi were positively associated with Lactobacillus species and IL-17A and negatively associated with BV-associated bacteria; these associations were most pronounced in the longer-term outcomes.IMPORTANCEVaginal colonization by fungi can enhance the risk of adverse reproductive health outcomes and HIV acquisition, potentially by eliciting genital mucosal inflammation. We show that standard antibiotic treatment for bacterial vaginosis (BV) results in a transient increase in the absolute abundance of vaginal fungi, most of which was identified as Candida albicans. Vaginal fungi were positively associated with proinflammatory immune factors and negatively associated with BV-associated bacteria. These findings improve our understanding of how shifts in the bacterial composition of the vaginal microbiota may enhance proliferation by proinflammatory vaginal fungi, which may have important implications for risk of adverse reproductive health outcomes among women.
- Published
- 2024
28. Targeting Lactobacillus johnsonii to reverse chronic kidney disease.
- Author
-
Miao, Hua, Liu, Fei, Wang, Yan-Ni, Yu, Xiao-Yong, Zhuang, Shougang, Guo, Yan, Vaziri, Nosratola, Ma, Shi-Xing, Su, Wei, Shang, You-Quan, Gao, Ming, Zhang, Jin-Hua, Zhang, Li, Zhao, Ying-Yong, and Cao, Gang
- Subjects
Renal Insufficiency ,Chronic ,Animals ,Rats ,Humans ,Mice ,Male ,Lactobacillus johnsonii ,Indoles ,Receptors ,Aryl Hydrocarbon ,Gastrointestinal Microbiome ,Female - Abstract
Accumulated evidence suggested that gut microbial dysbiosis interplayed with progressive chronic kidney disease (CKD). However, no available therapy is effective in suppressing progressive CKD. Here, using microbiomics in 480 participants including healthy controls and patients with stage 1-5 CKD, we identified an elongation taxonomic chain Bacilli-Lactobacillales-Lactobacillaceae-Lactobacillus-Lactobacillus johnsonii correlated with patients with CKD progression, whose abundance strongly correlated with clinical kidney markers. L. johnsonii abundance reduced with progressive CKD in rats with adenine-induced CKD. L. johnsonii supplementation ameliorated kidney lesion. Serum indole-3-aldehyde (IAld), whose level strongly negatively correlated with creatinine level in CKD rats, decreased in serum of rats induced using unilateral ureteral obstruction (UUO) and 5/6 nephrectomy (NX) as well as late CKD patients. Treatment with IAld dampened kidney lesion through suppressing aryl hydrocarbon receptor (AHR) signal in rats with CKD or UUO, and in cultured 1-hydroxypyrene-induced HK-2 cells. Renoprotective effect of IAld was partially diminished in AHR deficiency mice and HK-2 cells. Our further data showed that treatment with L. johnsonii attenuated kidney lesion by suppressing AHR signal via increasing serum IAld level. Taken together, targeting L. johnsonii might reverse patients with CKD. This study provides a deeper understanding of how microbial-produced tryptophan metabolism affects host disease and discovers potential pathways for prophylactic and therapeutic treatments for CKD patients.
- Published
- 2024
29. Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers.
- Author
-
Shariff, Bushra, Barnett, Reagan, Dayyani, Farshid, Maron, Steven, Mcgriskin, Rory, Klempner, Samuel, Donderici, Elifnur, Zhang, Nicole, Masannat, Jude, Drusbosky, Leylah, and Mehta, Rutika
- Subjects
FGFR2 amplification ,gastroesophageal cancer ,liquid biopsy ,real-world data ,Humans ,Receptor ,Fibroblast Growth Factor ,Type 2 ,Circulating Tumor DNA ,Esophageal Neoplasms ,Stomach Neoplasms ,Female ,Male ,Retrospective Studies ,Middle Aged ,Biomarkers ,Tumor ,Aged ,High-Throughput Nucleotide Sequencing ,Mutation ,Adult - Abstract
PURPOSE: In addition to the existing biomarkers HER2 and PD-L1, FGFR2b has become an area of interest for the development of new targeted-based treatment. Given that clinical evaluation of FGFR2 targeted therapy is underway, we sought to elucidate the genomic landscape of FGFR2amp in gastroesophageal cancer (GEC) using a circulating tumor DNA (ctDNA) platform. MATERIALS AND METHODS: We retrospectively evaluated the Guardant Health database from 2017 to 2022 for patients with GECs with Guardant360 ctDNA next-generation sequencing (NGS) performed. We assessed co-occurring genetic alterations for patients who harbored FGFR2amp versus FGFR2null. We also explored real-world evidence database with Guardant Health, publicly available genomic databases (MSK cohort using cBioPortal), and pooled clinical data from large-volume cancer centers for FGFR2amp GECs. RESULTS: Less than 4% of patients with GEC in the Guardant Health database were identified to be FGFR2amp. The most commonly co-occurring gene mutations were TP53, CTNNB1, CDH1, and RHOA. Upon interrogation of the MSK cohort, these same genes were not significant on tissue NGS in the FGFR2amp cohort of GEC. In the pooled institutional cohort, we noted that FGFR2amp tumors were most commonly involving the gastroesophageal junction (GEJ). The overall survival of these patients was noted at 13.1 months. CONCLUSION: FGFR2 is a validated target in GECs, and the contexture of FGFR2amp will be important in defining patient subgroups with responses to FGFR2-directed therapy. Using ctDNA to provide a more detailed genomic landscape in patients with GECs will allow the advancement of targeted therapy in the near future for these aggressive cancers.
- Published
- 2024
30. Phenotyping COVID-19 respiratory failure in spontaneously breathing patients with AI on lung CT-scan.
- Author
-
Rezoagli, Emanuele, Xin, Yi, Signori, Davide, Sun, Wenli, Gerard, Sarah, Delucchi, Kevin, Magliocca, Aurora, Vitale, Giovanni, Giacomini, Matteo, Mussoni, Linda, Montomoli, Jonathan, Subert, Matteo, Ponti, Alessandra, Spadaro, Savino, Poli, Giancarla, Casola, Francesco, Herrmann, Jacob, Foti, Giuseppe, Calfee, Carolyn, Laffey, John, Bellani, Giacomo, and Cereda, Maurizio
- Subjects
Artificial intelligence ,COVID-19 ,Computed tomography ,Latent class analysis ,Respiratory failure ,Subphenotypes ,Humans ,COVID-19 ,Tomography ,X-Ray Computed ,Female ,Male ,Middle Aged ,Phenotype ,Lung ,Aged ,Respiratory Insufficiency ,Cohort Studies ,Adult - Abstract
BACKGROUND: Automated analysis of lung computed tomography (CT) scans may help characterize subphenotypes of acute respiratory illness. We integrated lung CT features measured via deep learning with clinical and laboratory data in spontaneously breathing subjects to enhance the identification of COVID-19 subphenotypes. METHODS: This is a multicenter observational cohort study in spontaneously breathing patients with COVID-19 respiratory failure exposed to early lung CT within 7 days of admission. We explored lung CT images using deep learning approaches to quantitative and qualitative analyses; latent class analysis (LCA) by using clinical, laboratory and lung CT variables; regional differences between subphenotypes following 3D spatial trajectories. RESULTS: Complete datasets were available in 559 patients. LCA identified two subphenotypes (subphenotype 1 and 2). As compared with subphenotype 2 (n = 403), subphenotype 1 patients (n = 156) were older, had higher inflammatory biomarkers, and were more hypoxemic. Lungs in subphenotype 1 had a higher density gravitational gradient with a greater proportion of consolidated lungs as compared with subphenotype 2. In contrast, subphenotype 2 had a higher density submantellar-hilar gradient with a greater proportion of ground glass opacities as compared with subphenotype 1. Subphenotype 1 showed higher prevalence of comorbidities associated with endothelial dysfunction and higher 90-day mortality than subphenotype 2, even after adjustment for clinically meaningful variables. CONCLUSIONS: Integrating lung-CT data in a LCA allowed us to identify two subphenotypes of COVID-19, with different clinical trajectories. These exploratory findings suggest a role of automated imaging characterization guided by machine learning in subphenotyping patients with respiratory failure. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04395482. Registration date: 19/05/2020.
- Published
- 2024
31. A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.
- Author
-
Dayyani, Farshid, Chao, Joseph, Lee, Fa-Chyi, Taylor, Thomas, Neumann, Kristen, and Cho, May
- Subjects
ICI ,TKI ,gastroesophageal cancer ,immune checkpoint inhibitor ,Humans ,Female ,Middle Aged ,Male ,Pyridines ,Aged ,Anilides ,Antibodies ,Monoclonal ,Humanized ,Stomach Neoplasms ,Adult ,Aged ,80 and over ,Immune Checkpoint Inhibitors ,Adenocarcinoma ,Esophageal Neoplasms ,Drug Resistance ,Neoplasm ,Antineoplastic Combined Chemotherapy Protocols ,Young Adult ,Esophagogastric Junction - Abstract
BACKGROUND: Most patients with metastatic gastroesophageal adenocarcinoma (mGEA) progress on immune checkpoint inhibitors (ICIs). Novel approaches to overcome resistance to ICI in mGEA are needed. Cabozantinib is a multi-tyrosine kinase inhibitor thought to enhance the immunomodulatory effects of ICI. This study evaluated the combination of cabozantinib and pembrolizumab in ICI refractory or resistant mGEA. METHODS: Investigator-initiated, single-arm, single institution, and phase II study in patients with mGEA. Patients had progressed on ICI and/or had PD-L1 CPS score ≤10%. Cabozantinib dose was 40 mg p.o. daily on days 1-21 of a 21-day cycle, with pembrolizumab 200 mg i.v. on day 1. The primary endpoint was progression-free survival at 6 months (PFS-6). RESULTS: Twenty-seven patients were enrolled. Median age 58 years (24-87), female (n = 14), ECOG 0/1 = 13/14, GC/GEJ = 16/11, and non-Hispanic White/Hispanic/Asian = 12/8/7. The primary endpoint was met. After a median follow-up of 31.4 months (range 3.3-42.5), PFS-6 was 22.2% (95% CI 9.0-39.0). The median PFS and OS are 2.3 months (95% CI 1.7-4.1) and 5.5 months (3.1-14.0), respectively. The most common mutations were TP53 (78.3%) and CDH1/PIK3CA/CTNNB1 (17.4% each). The most common grade (G) treatment-related adverse events (TRAE) were diarrhea (25.9%), fatigue (18.5%), hypertension, and muscle cramps (14.8% each). G3-4 TRAE were seen in n = 3 patients (hypertension, thromboembolic event, esophageal perforation; each n = 1). No G5 was observed. CONCLUSIONS: The addition of cabozantinib to pembrolizumab shows clinical benefit in ICI-resistant or refractory mGEA with a tolerable safety profile. (ClinicalTrials.gov Identifier: NCT04164979. IRB Approved: UCI 18-124, University of California Irvine IRB#20195426.).
- Published
- 2024
32. Relationship between deltamethrin resistance and gut symbiotic bacteria of Aedes albopictus by 16S rDNA sequencing.
- Author
-
Sun, Yingbo, Li, Tingting, Zhou, Guofa, Zhou, Yunfei, Wu, Yuhong, Xu, Jiabao, Chen, Jiarong, Zhong, Saifeng, Zhong, Daibin, Liu, Rui, Lu, Gang, and Li, Yiji
- Subjects
16S rDNA ,Aedes albopictus ,Deltamethrin ,Gut commensal bacteria ,Insecticide resistance ,Animals ,Pyrethrins ,Nitriles ,Aedes ,Insecticide Resistance ,Insecticides ,Larva ,RNA ,Ribosomal ,16S ,Symbiosis ,Bacteria ,Gastrointestinal Microbiome ,Mosquito Vectors ,DNA ,Ribosomal ,Female ,DNA ,Bacterial ,Gastrointestinal Tract - Abstract
BACKGROUND: Aedes albopictus is an important vector for pathogens such as dengue, Zika, and chikungunya viruses. While insecticides is the mainstay for mosquito control, their widespread and excessive use has led to the increased resistance in Ae. albopictus globally. Gut symbiotic bacteria are believed to play a potential role in insect physiology, potentially linking to mosquitoes metabolic resistance against insecticides. METHODS: We investigated the role of symbiotic bacteria in the development of resistance in Ae. albopictus by comparing gut symbiotic bacteria between deltamethrin-sensitive and deltamethrin-resistant populations. Adults were reared from field-collected larvae. Sensitive and resistant mosquitoes were screened using 0.03% and 0.09% deltamethrin, respectively, on the basis of the World Health Organization (WHO) tube bioassay. Sensitive and resistant field-collected larvae were screened using 5 × LC50 (lethal concentration at 50% mortality) and 20 × LC50 concentration of deltamethrin, respectively. Laboratory strain deltamethrin-sensitive adults and larvae were used as controls. The DNA of gut samples from these mosquitoes were extracted using the magnetic bead method. Bacterial 16S rDNA was sequenced using BGISEQ method. We isolated and cultured gut microorganisms from adult and larvae mosquitoes using four different media: Luria Bertani (LB), brain heart infusion (BHI), nutrient agar (NA), and salmonella shigella (SS). RESULTS: Sequencing revealed significantly higher gut microbial diversity in field-resistant larvae compared with field-sensitive and laboratory-sensitive larvae (P
- Published
- 2024
33. Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project.
- Author
-
Schini, Marian, Vilaca, Tatiane, Lui, Li-Yung, Ewing, Susan, Thompson, Austin, Vittinghoff, Eric, Bauer, Douglas, Bouxsein, Mary, Black, Dennis, and Eastell, Richard
- Subjects
BMD ,SABRE ,T-score ,osteoporosis ,treatment ,Humans ,Bone Density ,Female ,Male ,Aged ,Middle Aged ,Risk Factors ,Fractures ,Bone ,Bone Density Conservation Agents ,Randomized Controlled Trials as Topic ,Spinal Fractures ,Osteoporosis - Abstract
Some osteoporosis drug trials have suggested that treatment is more effective in those with low BMD measured by DXA. This study used data from a large set of randomized controlled trials (RCTs) to determine whether the anti-fracture efficacy of treatments differs according to baseline BMD. We used individual patient data from 25 RCTs (103 086 subjects) of osteoporosis medications collected as part of the FNIH-ASBMR SABRE project. Participants were stratified into FN BMD T-score subgroups (≤-2.5, > -2.5). We used Cox proportional hazard regression to estimate treatment effect for clinical fracture outcomes and logistic regression for the radiographic vertebral fracture outcome. We also performed analyses based on BMD quintiles. Overall, 42% had a FN BMD T-score ≤ -2.5. Treatment with anti-osteoporosis drugs led to significant reductions in fractures in both T-score ≤ -2.5 and > -2.5 subgroups. Compared to those with FN BMD T-score > -2.5, the risk reduction for each fracture outcome was greater in those with T-score ≤ -2.5, but only the all-fracture outcome reached statistical significance (interaction P = .001). Results were similar when limited to bisphosphonate trials. In the quintile analysis, there was significant anti-fracture efficacy across all quintiles for vertebral fractures and with greater effects on fracture risk reduction for non-vertebral, all, and all clinical fractures in the lower BMD quintiles (all interaction P ≤ .03). In summary, anti-osteoporotic medications reduced the risk of fractures regardless of baseline BMD. Significant fracture risk reduction with treatment for 4 of the 5 fracture endpoints was seen in participants with T-scores above -2.5, though effects tended to be larger and more significant in those with baseline T-scores
- Published
- 2024
34. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
- Author
-
Zhu, Xiaolin, Chan, Emily, Turski, Michelle, Mendez, Carlos, Hsu, Sarah, Kumar, Vipul, Shipp, Chase, Jindal, Tanya, Chang, Kevin, Onodera, Courtney, Devine, W, Grenert, James, Stohr, Bradley, Ding, Chien-Kuang, Stachler, Matthew, Quigley, David, Feng, Felix, Chu, Carissa, Porten, Sima, Chou, Jonathan, Friedlander, Terence, and Koshkin, Vadim
- Subjects
ERBB2 amplification ,GATA3 ,PPARG ,HER2 ,urothelial cancer ,Humans ,GATA3 Transcription Factor ,Receptor ,ErbB-2 ,Female ,PPAR gamma ,Male ,DNA Copy Number Variations ,Urologic Neoplasms ,Aged ,Middle Aged ,Gene Amplification ,Biomarkers ,Tumor ,Urinary Bladder Neoplasms ,Gene Expression Regulation ,Neoplastic - Abstract
HER2, encoded by the ERBB2 gene, is an important druggable driver of human cancer gaining increasing importance as a therapeutic target in urothelial carcinoma (UC). The genomic underpinnings of HER2 overexpression in ERBB2 nonamplified UC are poorly defined. To address this knowledge gap, we investigated 172 UC tumors from patients treated at the University of California San Francisco, using immunohistochemistry and next-generation sequencing. We found that GATA3 and PPARG copy number gains individually predicted HER2 protein expression independently of ERBB2 amplification. To validate these findings, we interrogated the Memorial Sloan Kettering/The Cancer Genome Atlas (MSK/TCGA) dataset and found that GATA3 and PPARG copy number gains individually predicted ERBB2 mRNA expression independently of ERBB2 amplification. Our findings reveal a potential link between the luminal marker HER2 and the key transcription factors GATA3 and PPARG in UC and highlight the utility of examining GATA3 and PPARG copy number states to identify UC tumors that overexpress HER2 in the absence of ERBB2 amplification. In summary, we found that an increase in copy number of GATA3 and PPARG was independently associated with higher ERBB2 expression in patient samples of UC. This finding provides a potential explanation for HER2 overexpression in UC tumors without ERBB2 amplification and a way to identify these tumors for HER2-targeted therapies.
- Published
- 2024
35. Multiplexed volumetric CLEM enabled by scFvs provides insights into the cytology of cerebellar cortex.
- Author
-
Han, Xiaomeng, Lu, Xiaotang, Li, Peter, Wang, Shuohong, Schalek, Richard, Meirovitch, Yaron, Lin, Zudi, Adhinarta, Jason, Murray, Karl, MacNiven, Leah, Berger, Daniel, Wu, Yuelong, Fang, Tao, Meral, Elif, Asraf, Shadnan, Ploegh, Hidde, Pfister, Hanspeter, Wei, Donglai, Jain, Viren, Trimmer, James, and Lichtman, Jeff
- Subjects
Animals ,Female ,Mice ,Cerebellar Cortex ,Microscopy ,Confocal ,Microscopy ,Electron ,Connectome ,Neurons ,Fluorescent Dyes ,Mice ,Inbred C57BL ,Cytology - Abstract
Mapping neuronal networks is a central focus in neuroscience. While volume electron microscopy (vEM) can reveal the fine structure of neuronal networks (connectomics), it does not provide molecular information to identify cell types or functions. We developed an approach that uses fluorescent single-chain variable fragments (scFvs) to perform multiplexed detergent-free immunolabeling and volumetric-correlated-light-and-electron-microscopy on the same sample. We generated eight fluorescent scFvs targeting brain markers. Six fluorescent probes were imaged in the cerebellum of a female mouse, using confocal microscopy with spectral unmixing, followed by vEM of the same sample. The results provide excellent ultrastructure superimposed with multiple fluorescence channels. Using this approach, we documented a poorly described cell type, two types of mossy fiber terminals, and the subcellular localization of one type of ion channel. Because scFvs can be derived from existing monoclonal antibodies, hundreds of such probes can be generated to enable molecular overlays for connectomic studies.
- Published
- 2024
36. Workplace support for physicians during the COVID-19 Pandemic: Did it affect burnout?
- Author
-
Melnikow, Joy, Xing, Guibo, Miller, Marykate, Loureiro, Sabrina, Padovani, Andrew, Whitney, Robin, and Kravitz, Richard
- Subjects
COVID-19 ,Frontline physicians ,Physician burnout ,Physician wellbeing ,Workplace support ,Humans ,COVID-19 ,Burnout ,Professional ,Male ,Female ,Physicians ,Adult ,SARS-CoV-2 ,Workplace ,Middle Aged ,Pandemics ,United States ,Surveys and Questionnaires - Abstract
BACKGROUND: A concern before 2020, physician burnout worsened during the COVID-19 pandemic. Little empirical data are available on pandemic workplace support interventions or their influence on burnout. We surveyed a national sample of frontline physicians on burnout and workplace support during the pandemic. METHODS: We surveyed a stratified random sample of 12,833 US physicians most likely to care for adult COVID-19 patients from the comprehensive AMA Physician Professional Data ™ file. The sample included 6722 primary care physicians (3331 family physicians, 3391 internists), 880 hospitalists, 1783 critical care physicians (894 critical care physicians, 889 pulmonary intensivists), 2548 emergency medicine physicians, and 900 infectious disease physicians. The emailed survey elicited physicians perceptions of organizational interventions to provide workplace support and/or to address burnout. Burnout was assessed with the Professional Fulfillment Index Burnout Composite scale (PFI-BC). Proportional specialty representation and response bias were addressed by survey weighting. Logistic regression assessed the association of physician characteristics and workplace interventions with burnout. RESULTS: After weighting, respondents were representative of the total sample. Overall physician burnout was 45.4%, significantly higher than in our previous survey. Open-ended responses mentioned that staffing shortages (physician, nursing, and other staff) combined with the increased volume, complexity, and acuity of patients during the pandemic increased job demands. The most frequent workplace support interventions were direct pandemic control measures (increased access to personal protective equipment, 70.0%); improved telehealth functionality (43.4%); and individual resiliency tools (yoga, meditation, 30.7%). Respondents placed highest priority on workplace interventions to increase financial support and increase nursing and clinician staffing. Factors significantly associated with lower odds of burnout were practicing critical care (compared with emergency medicine) OR 0.33 (95% CI 0.12 - 0.93), improved telehealth functionality OR 0.47 (95% CI 0.23 - 0.97) and being in practice for 11 years or longer OR 0.44 (95% CI 0.19-0.99). CONCLUSIONS: Burnout across frontline specialties increased during the pandemic. Physician respondents focused on inadequate staffing in the context of caring for more and sicker patients, combined with the lack of administrative efforts to mitigate problems. Burnout mitigation requires system-level interventions beyond individual-focused stress reduction programs to improve staffing, increase compensation, and build effective teams.
- Published
- 2024
37. DSBSO-Based XL-MS Analysis of Breast Cancer PDX Tissues to Delineate Protein Interaction Network in Clinical Samples.
- Author
-
Jiao, Fenglong, Yu, Clinton, Wheat, Andrew, Chen, Lijun, Lih, Tung-Shing, Zhang, Hui, and Huang, Lan
- Subjects
Alkyne-A-DSBSO ,PDX ,PPI ,XL-MS ,breast cancer ,Humans ,Breast Neoplasms ,Protein Interaction Maps ,Female ,Animals ,Mass Spectrometry ,Mice ,Proteome ,Proteomics ,Protein Interaction Mapping - Abstract
Protein-protein interactions (PPIs) are fundamental to understanding biological systems as protein complexes are the active molecular modules critical for carrying out cellular functions. Dysfunctional PPIs have been associated with various diseases including cancer. Systems-wide PPI analysis not only sheds light on pathological mechanisms, but also represents a paradigm in identifying potential therapeutic targets. In recent years, cross-linking mass spectrometry (XL-MS) has emerged as a powerful tool for defining endogenous PPIs of cellular networks. While proteome-wide studies have been performed in cell lysates, intact cells and tissues, applications of XL-MS in clinical samples have not been reported. In this study, we adopted a DSBSO-based in vivo XL-MS platform to map interaction landscapes from two breast cancer patient-derived xenograft (PDX) models. As a result, we have generated a PDX interaction network comprising 2,557 human proteins and identified interactions unique to breast cancer subtypes. Interestingly, most of the observed differences in PPIs correlated well with protein abundance changes determined by TMT-based proteome quantitation. Collectively, this work has demonstrated the feasibility of XL-MS analysis in clinical samples, and established an analytical workflow for tissue cross-linking that can be generalized for mapping PPIs from patient samples in the future to dissect disease-relevant cellular networks.
- Published
- 2024
38. Wireless ear EEG to monitor drowsiness.
- Author
-
Kaveh, Ryan, Schwendeman, Carolyn, Pu, Leslie, Arias, Ana, and Muller, Rikky
- Subjects
Humans ,Electroencephalography ,Wireless Technology ,Wearable Electronic Devices ,Male ,Adult ,Sleep Stages ,Female ,Ear ,Electrodes ,Algorithms ,Support Vector Machine ,Young Adult ,Monitoring ,Physiologic - Abstract
Neural wearables can enable life-saving drowsiness and health monitoring for pilots and drivers. While existing in-cabin sensors may provide alerts, wearables can enable monitoring across more environments. Current neural wearables are promising but most require wet-electrodes and bulky electronics. This work showcases in-ear, dry-electrode earpieces used to monitor drowsiness with compact hardware. The employed system integrates additive-manufacturing for dry, user-generic earpieces, existing wireless electronics, and offline classification algorithms. Thirty-five hours of electrophysiological data were recorded across nine subjects performing drowsiness-inducing tasks. Three classifier models were trained with user-specific, leave-one-trial-out, and leave-one-user-out splits. The support-vector-machine classifier achieved an accuracy of 93.2% while evaluating users it has seen before and 93.3% when evaluating a never-before-seen user. These results demonstrate wireless, dry, user-generic earpieces used to classify drowsiness with comparable accuracies to existing state-of-the-art, wet electrode in-ear and scalp systems. Further, this work illustrates the feasibility of population-trained classification in future electrophysiological applications.
- Published
- 2024
39. Im Walking into Spiderwebs: Making Sense of Protein-Protein Interaction Data.
- Author
-
Skawinski, Chase and Shah, Priya
- Subjects
mass spectrometry ,protein−protein interactions ,proteomic scoring ,Proteomics ,Humans ,Mass Spectrometry ,Protein Interaction Mapping ,Female ,Protein Interaction Maps ,Proteins - Abstract
Protein-protein interactions (PPIs) are at the heart of the molecular landscape permeating life. Proteomics studies can explore this protein interaction landscape using mass spectrometry (MS). Thanks to their high sensitivity, mass spectrometers can easily identify thousands of proteins within a single sample, but that same sensitivity generates tangled spiderwebs of data that hide biologically relevant findings. So, what does a researcher do when she finds herself walking into spiderwebs? In a field focused on discovery, MS data require rigor in their analysis, experimental validation, or a combination of both. In this Review, we provide a brief primer on MS-based experimental methods to identify PPIs. We discuss approaches to analyze the resulting data and remove the proteomic background. We consider the advantages between comprehensive and targeted studies. We also discuss how scoring might be improved through AI-based protein structure information. Women have been essential to the development of proteomics, so we will specifically highlight work by women that has made this field thrive in recent years.
- Published
- 2024
40. The association between reproductive history and abdominal adipose tissue among postmenopausal women: results from the Womens Health Initiative.
- Author
-
Banack, Hailey, Cook, Claire, Grandi, Sonia, Scime, Natalie, Andary, Rana, Follis, Shawna, Allison, Matthew, Manson, JoAnn, Jung, Su, Wild, Robert, Farland, Leslie, Shadyab, Aladdin, Bea, Jennifer, and Odegaard, Andrew
- Subjects
abdominal adiposity ,adiposity ,aging ,body composition ,menarche ,menopause ,obesity ,postmenopausal ,reproductive health ,women’s health ,Humans ,Female ,Postmenopause ,Middle Aged ,Reproductive History ,Menarche ,Aged ,Prospective Studies ,Womens Health ,Abdominal Fat ,Pregnancy ,Body Mass Index ,Parity ,Menopause ,Intra-Abdominal Fat ,Adiposity - Abstract
STUDY QUESTION: What is the association between reproductive health history (e.g. age at menarche, menopause, reproductive lifespan) with abdominal adiposity in postmenopausal women? SUMMARY ANSWER: Higher visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) tissue levels were observed among women with earlier menarche, earlier menopause, and greater parity. WHAT IS KNOWN ALREADY: Postmenopausal women are predisposed to accumulation of VAT and SAT. Reproductive health variables are known predictors of overall obesity status in women, defined by BMI. STUDY DESIGN, SIZE, DURATION: This study is a secondary analysis of data collected from the baseline visit of the Womens Health Initiative (WHI). The WHI is a large prospective study of postmenopausal women, including both a randomized trial and observational study. There were 10 184 women included in this analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Data were collected from a reproductive health history questionnaire, dual-energy x-ray absorptiometry scans, and anthropometric measures at WHI baseline. Reproductive history was measured via self-report, and included age at menarche, variables related to pregnancy, and age at menopause. Reproductive lifespan was calculated as age at menopause minus age at menarche. Statistical analyses included descriptive analyses and multivariable linear regression models to examine the association between reproductive history with VAT, SAT, total body fat, and BMI. MAIN RESULTS AND THE ROLE OF CHANCE: Women who reported early menarche (15 years had 23 cm2 less VAT (95% CI: -31.4, -14.4) and 47 cm2 less SAT (95% CI: -61.8, -33.4) than women who experienced menarche at age 10 years or earlier. A similar pattern was observed for age at menopause: compared to women who experienced menopause 3 pregnancies) was also associated with VAT and SAT. For example, adjusted beta coefficients for VAT were 8.36 (4.33, 12.4) and 17.9 (12.6, 23.2) comparing three to four pregnancies with the referent, one to two pregnancies. LIMITATIONS, REASONS FOR CAUTION: The WHI reproductive health history questionnaire may be subject to poor recall owing to a long look-back window. Residual confounding may be present given lack of data on early life characteristics, such as maternal and pre-menarche characteristics. WIDER IMPLICATIONS OF THE FINDINGS: This study contributes to our understanding of reproductive lifespan, including menarche and menopause, as an important predictor of late-life adiposity in women. Reproductive health has also been recognized as a sentinel marker for chronic disease in late life. Given established links between adiposity and cardiometabolic outcomes, this research has implications for future research, clinical practice, and public health policy that makes use of reproductive health history as an opportunity for chronic disease prevention. STUDY FUNDING/COMPETING INTEREST(S): HRB and AOO are supported by the National Institute of Health National Institute of Aging (R01AG055018-04). JWB reports royalties from ACSMS Body Composition Assessment Book and consulting fees from the WHI. The remaining authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.
- Published
- 2024
41. Strontium isotopes track female dispersal in Taï chimpanzees
- Author
-
Boucher, Renee D, Wittig, Roman M, Lemoine, Sylvain RT, Maro, Aleksey, Wang, Xueye, Koch, Paul L, and Oelze, Vicky M
- Subjects
Anthropology ,Human Society ,Animals ,Pan troglodytes ,Female ,Cote d'Ivoire ,Strontium Isotopes ,Male ,Animal Distribution ,Anthropology ,Physical ,chimpanzees ,dispersal ,enamel ,isoscape ,Sr isotopes ,Evolutionary Biology ,Archaeology ,Ecology - Abstract
ObjectivesChimpanzees (Pan troglodytes) are patrilocal, with males remaining in their natal community and females dispersing when they reach sexual maturity. However, the details of female chimpanzee dispersal, such as their possible origin, are difficult to assess, even in habituated communities. This study investigates the utility of 87Sr/86Sr analysis for (1) assessing Sr baseline differences between chimpanzee territories and (2) identifying the status (immigrant or natal) of females of unknown origin within the territories of five neighboring communities in Taï National Park (Côte d'Ivoire).Materials and methodsTo create a local Sr isoscape for the Taï Chimpanzee Project (TCP) study area, we sampled environmental samples from TCP-established territories (n = 35). To assess dispersal patterns, 34 tooth enamel samples (one per individual) were selected from the Taï chimpanzee skeletal collection. 87Sr/86Sr analysis was performed on all 69 samples at the W.M. Keck Lab. The theoretical density and overlap of chimpanzee communities as well as generalized linear mixed models (GLMMs) were used to test each question.Results87Sr/86Sr ratios for natal male chimpanzees ranged from 0.71662 to 0.72187, which is well within the corresponding environmental baseline range of 0.70774-0.73460. The local Sr isoscapes fit was estimated with the root-mean-square error value, which was 0.0048 (22% of the whole 87Sr/86Sr data range). GLMMs identified significant differences in 87Sr/86Sr ratios between natal and unknown North community origin groups, suggesting that after 1980, females of unknown origin could be immigrants to North community (n = 7, z-ratio = -4.08, p = 0.0001, power = 0.94).DiscussionThis study indicates that 87Sr/86This study indicates that 87Sr/86Sr analysis can successfully identify immigrant females in skeletal collections obtained from wild chimpanzee communities, enabling the tracking of female dispersal patterns historically. There are, however, significant limitations within the scope of this study, such as (1) the absence of reliable maps for the TCP study area, (2) limited capacity for environmental sampling, (3) small sample sizes, and (4) tooth formation in wild chimpanzees.
- Published
- 2024
42. Parkinsons disease variant detection and disclosure: PD GENEration, a North American study.
- Author
-
Cook, Lola, Verbrugge, Jennifer, Schwantes-An, Tae-Hwi, Schulze, Jeanine, Foroud, Tatiana, Hall, Anne, Marder, Karen, Mata, Ignacio, Mencacci, Niccolò, Nance, Martha, Schwarzschild, Michael, Simuni, Tanya, Bressman, Susan, Wills, Anne-Marie, Fernandez, Hubert, Litvan, Irene, Lyons, Kelly, Shill, Holly, Singer, Carlos, Tropea, Thomas, Vanegas Arroyave, Nora, Carbonell, Janfreisy, Cruz Vicioso, Rossy, Katus, Linn, Quinn, Joseph, Hodges, Priscila, Meng, Yan, Strom, Samuel, Blauwendraat, Cornelis, Lohmann, Katja, Casaceli, Cynthia, Rao, Shilpa, Ghosh Galvelis, Kamalini, Naito, Anna, Beck, James, and Alcalay, Roy
- Subjects
GBA1 ,LRRK2 ,Parkinson’s disease ,clinical trials ,genetic counselling ,genetic testing ,Humans ,Parkinson Disease ,Genetic Testing ,Male ,Female ,Glucosylceramidase ,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 ,alpha-Synuclein ,Aged ,Middle Aged ,Ubiquitin-Protein Ligases ,Protein Kinases ,Protein Deglycase DJ-1 ,Vesicular Transport Proteins ,North America ,Genetic Variation ,Genetic Predisposition to Disease ,Adult ,Disclosure ,Genetic Counseling ,Canada ,United States - Abstract
Variants in seven genes (LRRK2, GBA1, PRKN, SNCA, PINK1, PARK7 and VPS35) have been formally adjudicated as causal contributors to Parkinsons disease; however, individuals with Parkinsons disease are often unaware of their genetic status since clinical testing is infrequently offered. As a result, genetic information is not incorporated into clinical care, and variant-targeted precision medicine trials struggle to enrol people with Parkinsons disease. Understanding the yield of genetic testing using an established gene panel in a large, geographically diverse North American population would help patients, clinicians, clinical researchers, laboratories and insurers better understand the importance of genetics in approaching Parkinsons disease. PD GENEration is an ongoing multi-centre, observational study (NCT04057794, NCT04994015) offering genetic testing with results disclosure and genetic counselling to those in the US (including Puerto Rico), Canada and the Dominican Republic, through local clinical sites or remotely through self-enrolment. DNA samples are analysed by next-generation sequencing including deletion/duplication analysis (Fulgent Genetics) with targeted testing of seven major Parkinsons disease-related genes. Variants classified as pathogenic/likely pathogenic/risk variants are disclosed to all tested participants by either neurologists or genetic counsellors. Demographic and clinical features are collected at baseline visits. Between September 2019 and June 2023, the study enrolled 10 510 participants across >85 centres, with 8301 having received results. Participants were: 59% male; 86% White, 2% Asian, 4% Black/African American, 9% Hispanic/Latino; mean age 67.4 ± 10.8 years. Reportable genetic variants were observed in 13% of all participants, including 18% of participants with one or more high risk factors for a genetic aetiology: early onset (
- Published
- 2024
43. Assessing the impact of glazing and window shade systems on view clarity.
- Author
-
Ko, Won, Burgess, Isabel, Schiavon, Stefano, Chung, Susana, MacNaughton, Piers, and Um, Chai
- Subjects
Humans ,Vision Tests ,Color Perception ,Contrast Sensitivity ,Glare ,Visual Acuity ,Adult ,Female ,Male ,Young Adult - Abstract
Windows provide access to daylight and outdoor views, influencing building design. Various glazing and window shade materials are used to mitigate glare, overheating and privacy issues, and they affect view clarity. Among them, we evaluated the effect of window films, electrochromic (EC) glass, and fabric shades on view clarity. We conducted an experiment with 50 participants using visual tests adapted from clinical vision tests (visual acuity, contrast sensitivity, color sensitivity) and images displayed on a computer monitor in a controlled laboratory. Window films and EC glass tints outperformed fabric shades in visual acuity, contrast sensitivity and view satisfaction with the exception of the darkest EC tint state and dark grey VLT 3% shade for color sensitivity and view satisfaction. The EC tints pose internal reflection issues and fabric shades are preferred for visual privacy. Window films and EC glass hinder participants blue-green color discrimination while fabric shades also decrease red-yellow color discrimination. Visual acuity predicts view satisfaction and contrast sensitivity is the strongest predictor for visual privacy. Generally, higher visible light transmittance and lower solar reflectance (darker color) enhance human visual performance. The proposed workflow provides an experimental procedure, identifies the primary variables and establishes a predictive framework for assessing view clarity of fenestration.
- Published
- 2024
44. Factors Associated With Visual Field Testing Reliability in Children With Glaucoma or Suspected Glaucoma.
- Author
-
Kumar, Anika, Hekmatjah, Natan, Yu, Yinxi, Han, Ying, Ying, Gui-Shuang, and Oatts, Julius
- Subjects
Humans ,Female ,Child ,Retrospective Studies ,Male ,Visual Fields ,Reproducibility of Results ,Visual Field Tests ,Visual Acuity ,Intraocular Pressure ,Adolescent ,Glaucoma ,Child ,Preschool ,Ocular Hypertension ,Risk Factors - Abstract
PURPOSE: To evaluate Humphrey Visual Field (HVF) test reliability and its associated risk factors in children with glaucoma or glaucoma suspect. DESIGN: Retrospective cohort study. METHODS: None. SETTING: Single-center childhood glaucoma clinic. PATIENT POPULATION: One hundred thirty-six patients aged ≤18 years with glaucoma/glaucoma suspect, and least 1 completed 24 to 2 HVF test between 2018 and 2023. OBSERVATION PROCEDURE: Demographic and clinical characteristics including age, primary language, visual acuity (VA), and glaucoma diagnosis were extracted from electronic health records. MAIN OUTCOME MEASURES: HVF 24 to 2 testing metrics, including FP, FN, and FL. Tests were defined as reliable using manufacturer guidelines of ≤33% FP, ≤33% FN, and ≤20% FL. For each patient, a reliability score was calculated as the percentage of reliable tests among all tests completed. A multivariable logistic regression model was used to determine factors associated with test-level reliability (yes/no). A multivariable linear regression model was used to determine factors associated with patient-level reliability score. RESULTS: Among 634 HVFs from 136 patients (Mean ± SD age at first test 12.0 ± 3.2 years, 47.8% female), 51.3% were reliable. Older age, better baseline VA, and English as primary language were associated with greater odds of test-level reliability (P < .04). Mean ± SD patient-level reliability score was 51.7 ± 38.1%. Older age at first clinic visit, better baseline VA, and English as primary language were associated with higher reliability scores (all P < .02), and number of prior VF tests was not (P = .56). CONCLUSIONS: Younger age, worse visual acuity, and non-English as primary language were associated with decreased reliability and should be considered when interpreting VF testing in children. A significant learning effect was not observed with repeated testing.
- Published
- 2024
45. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinsons disease study.
- Author
-
Westenberger, Ana, Skrahina, Volha, Usnich, Tatiana, Beetz, Christian, Vollstedt, Eva-Juliane, Laabs, Björn-Hergen, Paul, Jefri, Curado, Filipa, Skobalj, Snezana, Gaber, Hanaa, Olmedillas, Maria, Bogdanovic, Xenia, Ameziane, Najim, Schell, Nathalie, Aasly, Jan, Afshari, Mitra, Agarwal, Pinky, Aldred, Jason, Alonso-Frech, Fernando, Anderson, Roderick, Araújo, Rui, Arkadir, David, Avenali, Micol, Balal, Mehmet, Benizri, Sandra, Bette, Sagari, Bhatia, Perminder, Bonello, Michael, Braga-Neto, Pedro, Brauneis, Sarah, Cardoso, Francisco, Cavallieri, Francesco, Classen, Joseph, Cohen, Lisa, Coletta, Della, Crosiers, David, Cullufi, Paskal, Dashtipour, Khashayar, Demirkiran, Meltem, de Carvalho Aguiar, Patricia, De Rosa, Anna, Djaldetti, Ruth, Dogu, Okan, Dos Santos Ghilardi, Maria, Eggers, Carsten, Elibol, Bulent, Ellenbogen, Aaron, Ertan, Sibel, Fabiani, Giorgio, Falkenburger, Björn, Farrow, Simon, Fay-Karmon, Tsviya, Ferencz, Gerald, Fonoff, Erich, Fragoso, Yara, Genç, Gençer, Gorospe, Arantza, Grandas, Francisco, Gruber, Doreen, Gudesblatt, Mark, Gurevich, Tanya, Hagenah, Johann, Hanagasi, Hasmet, Hassin-Baer, Sharon, Hauser, Robert, Hernández-Vara, Jorge, Herting, Birgit, Hinson, Vanessa, Hogg, Elliot, Hu, Michele, Hummelgen, Eduardo, Hussey, Kelly, Infante, Jon, Isaacson, Stuart, Jauma, Serge, Koleva-Alazeh, Natalia, Kuhlenbäumer, Gregor, Kühn, Andrea, Litvan, Irene, López-Manzanares, Lydia, Luxmore, McKenzie, Manandhar, Sujeena, Marcaud, Veronique, Markopoulou, Katerina, Marras, Connie, McKenzie, Mark, Matarazzo, Michele, Merello, Marcelo, Mollenhauer, Brit, Morgan, John, Mullin, Stephen, Musacchio, Thomas, Myers, Bennett, Negrotti, Anna, Nieves, Anette, Nitsan, Zeev, Oskooilar, Nader, Öztop-Çakmak, Özgür, Pal, Gian, and Pavese, Nicola
- Subjects
GBA1 ,LRRK2 ,Parkinson’s disease ,genetic factors ,genetic testing ,next-generation sequencing ,Humans ,Parkinson Disease ,Male ,Female ,Middle Aged ,Aged ,Genetic Testing ,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 ,Glucosylceramidase ,alpha-Synuclein ,Genetic Predisposition to Disease ,Ubiquitin-Protein Ligases ,Cohort Studies ,Protein Kinases ,Mutation ,Adult - Abstract
Estimates of the spectrum and frequency of pathogenic variants in Parkinsons disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the clinical trial stage, a major obstacle in conducting these trials is that PD patients are largely unaware of their genetic status and, therefore, cannot be recruited. Expanding the number of investigated PD-related genes and including genes related to disorders with overlapping clinical features in large, well-phenotyped PD patient groups is a prerequisite for capturing the full variant spectrum underlying PD and for stratifying and prioritizing patients for gene-targeted clinical trials. The Rostock Parkinsons disease (ROPAD) study is an observational clinical study aiming to determine the frequency and spectrum of genetic variants contributing to PD in a large international cohort. We investigated variants in 50 genes with either an established relevance for PD or possible phenotypic overlap in a group of 12 580 PD patients from 16 countries [62.3% male; 92.0% White; 27.0% positive family history (FH+), median age at onset (AAO) 59 years] using a next-generation sequencing panel. Altogether, in 1864 (14.8%) ROPAD participants (58.1% male; 91.0% White, 35.5% FH+, median AAO 55 years), a PD-relevant genetic test (PDGT) was positive based on GBA1 risk variants (10.4%) or pathogenic/likely pathogenic variants in LRRK2 (2.9%), PRKN (0.9%), SNCA (0.2%) or PINK1 (0.1%) or a combination of two genetic findings in two genes (∼0.2%). Of note, the adjusted positive PDGT fraction, i.e. the fraction of positive PDGTs per country weighted by the fraction of the population of the world that they represent, was 14.5%. Positive PDGTs were identified in 19.9% of patients with an AAO ≤ 50 years, in 19.5% of patients with FH+ and in 26.9% with an AAO ≤ 50 years and FH+. In comparison to the idiopathic PD group (6846 patients with benign variants), the positive PDGT group had a significantly lower AAO (4 years, P = 9 × 10-34). The probability of a positive PDGT decreased by 3% with every additional AAO year (P = 1 × 10-35). Female patients were 22% more likely to have a positive PDGT (P = 3 × 10-4), and for individuals with FH+ this likelihood was 55% higher (P = 1 × 10-14). About 0.8% of the ROPAD participants had positive genetic testing findings in parkinsonism-, dystonia/dyskinesia- or dementia-related genes. In the emerging era of gene-targeted PD clinical trials, our finding that ∼15% of patients harbour potentially actionable genetic variants offers an important prospect to affected individuals and their families and underlines the need for genetic testing in PD patients. Thus, the insights from the ROPAD study allow for data-driven, differential genetic counselling across the spectrum of different AAOs and family histories and promote a possible policy change in the application of genetic testing as a routine part of patient evaluation and care in PD.
- Published
- 2024
46. Intergrader Agreement in Grading Optical Coherence Tomography Morphologic Features in Eyes With Intermediate Nonexudative Age-Related Macular Degeneration.
- Author
-
Carvajal, Nicole, Yang, Daphne, Nava, Kiana, Kedia, Anjani, Keenan, Jeremy, Yiu, Glenn, and Stewart, Jay
- Subjects
Humans ,Tomography ,Optical Coherence ,Aged ,Female ,Male ,Reproducibility of Results ,Macular Degeneration ,Observer Variation ,Middle Aged ,Aged ,80 and over ,Retinal Pigment Epithelium ,Retinal Drusen ,Severity of Illness Index - Abstract
PURPOSE: To determine the reliability of a nine-point summary scale for grading intermediate age-related macular degeneration (AMD) image morphologic features based on the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. METHODS: Two trained graders independently divided spectral domain-optical coherence tomography (SD-OCT) scans into nine subfields and then graded each subfield for the presence of intraretinal hyperreflective foci (HRF), reticular pseudodrusen (RPD), and incomplete or complete retinal pigment epithelium and outer retinal atrophy (iRORA or cRORA). Grading results were assessed by summing the subfield grades into a nine-point summary score and also by using an eye-level binary grade for presence of the finding in any subfield. Gwets first-order agreement coefficient (AC1) was calculated to assess intergrader agreement. RESULTS: Images of 79 eyes from 52 patients were evaluated. Intergrader agreement was higher when the OCT grades were summarized with a nine-point summary score (Gwets AC1 0.92, 0.89, 0.99, and 0.99 for HRF, RPD, iRORA, and cRORA, respectively) compared with the eye-level binary grade (Gwets AC1 0.75, 0.76, 0.97, and 0.96 for HRF, RPD, iRORA, and cRORA, respectively), with significant differences detected for HRF and RPD. CONCLUSIONS: The use of a nine-point summary score showed higher reliability in grading when compared to the binary subfield- and eye-level data, and thus may offer more precise estimation of AMD disease staging. TRANSLATIONAL RELEVANCE: These findings suggest that a nine-point summary score could be a useful means of disease staging by using findings on OCT in clinical studies of AMD.
- Published
- 2024
47. Wild raccoons demonstrate flexibility and individuality in innovative problem-solving
- Author
-
Stanton, Lauren A, Cooley-Ackermann, Carissa, Davis, Emily C, Fanelli, Rachel E, and Benson-Amram, Sarah
- Subjects
Climate Change Impacts and Adaptation ,Environmental Sciences ,Animals ,Problem Solving ,Raccoons ,Male ,Individuality ,Female ,carnivore ,cognition ,learning ,inhibitory control ,puzzle box ,urban ,Biological Sciences ,Agricultural and Veterinary Sciences ,Medical and Health Sciences ,Agricultural ,veterinary and food sciences ,Biological sciences ,Environmental sciences - Abstract
Cognitive skills, such as innovative problem-solving, are hypothesized to aid animals in urban environments. However, the significance of innovation in wild populations, and its expression across individuals and socio-ecological conditions, is poorly understood. To identify how and when innovation arises in urban-dwelling species, we used advanced technologies and new testing and analytical methods to evaluate innovative problem-solving abilities of wild raccoons (Procyon lotor). We deployed multi-compartment puzzle boxes with either one or multiple solution types and identified raccoons using radio frequency identification. Raccoons solved these novel extractive foraging tasks, and their success was influenced by age and exploratory diversity. Successful raccoons always discovered multiple different solution types, highlighting flexible problem-solving. Using a unique, comparative sequence analysis approach, we found that variation in raccoon solving techniques was greater between individuals than within individuals, and this self-similarity intensified during times of competition. Finally, the inclusion of an easier solution in the multi-solution trials enabled previously unsuccessful raccoons to bootstrap their learning and successfully open multiple difficult solutions. Our study suggests that innovative problem-solving is probably influenced by many factors and has provided novel field and analytical methods, as well as new insights on the socio-ecological dynamics of urban populations.
- Published
- 2024
48. The association between dietary fiber intake and gastric cancer: a pooled analysis of 11 case-control studies.
- Author
-
Collatuzzo, Giulia, Cortez Lainez, Jacqueline, Pelucchi, Claudio, Negri, Eva, Bonzi, Rossella, Palli, Domenico, Ferraroni, Monica, Zhang, Zuofeng, Yu, Guo-Pei, Lunet, Nuno, Morais, Samantha, López-Carrillo, Lizbeth, Zaridze, David, Maximovitch, Dmitry, Guevara, Marcela, Santos-Sanchez, Vanessa, Vioque, Jesus, Garcia de la Hera, Manoli, Ward, Mary, Malekzadeh, Reza, Pakseresht, Mohammadreza, Hernández-Ramírez, Raúl, Turati, Federica, Rabkin, Charles, Liao, Linda, Sinha, Rashmi, López-Cervantes, Malaquias, Tsugane, Shoichiro, Hidaka, Akihisa, Camargo, M, Curado, Maria, Zubair, Nadia, Kristjansson, Dana, Shah, Shailja, La Vecchia, Carlo, and Boffetta, Paolo
- Subjects
Cardia ,Dietary fiber ,Fiber intake ,Gastric cancer ,Gastric neoplasm ,Non-cardia ,Aged ,Female ,Humans ,Male ,Middle Aged ,Case-Control Studies ,Diet ,Dietary Fiber ,Fruit ,Logistic Models ,Odds Ratio ,Risk Factors ,Stomach Neoplasms ,Surveys and Questionnaires ,Vegetables - Abstract
PURPOSE: Gastric cancer (GC) is among the leading causes of cancer mortality worldwide. The objective of this study was to investigate the association between dietary fiber intake and GC. METHODS: We pooled data from 11 population or hospital-based case-control studies included in the Stomach Cancer Pooling (StoP) Project, for a total of 4865 histologically confirmed cases and 10,626 controls. Intake of dietary fibers and other dietary factors was collected using food frequency questionnaires. We calculated the odds ratios (OR) and 95% confidence intervals (CI) of the association between dietary fiber intake and GC by using a multivariable logistic regression model adjusted for study site, sex, age, caloric intake, smoking, fruit and vegetable intake, and socioeconomic status. We conducted stratified analyses by these factors, as well as GC anatomical site and histological type. RESULTS: The OR of GC for an increase of one quartile of fiber intake was 0.91 (95% CI: 0.85, 0.97), that for the highest compared to the lowest quartile of dietary fiber intake was 0.72 (95% CI: 0.59, 0.88). Results were similar irrespective of anatomical site and histological type. CONCLUSION: Our analysis supports the hypothesis that dietary fiber intake may exert a protective effect on GC.
- Published
- 2024
49. Derivation and transcriptional reprogramming of border-forming wound repair astrocytes after spinal cord injury or stroke in mice.
- Author
-
OShea, Timothy, Ao, Yan, Wang, Shinong, Ren, Yilong, Cheng, Amy, Kawaguchi, Riki, Shi, Zechuan, Swarup, Vivek, and Sofroniew, Michael
- Subjects
Animals ,Astrocytes ,Spinal Cord Injuries ,Mice ,Male ,Wound Healing ,Female ,Stroke ,Mice ,Inbred C57BL ,Cellular Reprogramming ,Oligodendrocyte Precursor Cells ,Cell Proliferation - Abstract
Central nervous system (CNS) lesions become surrounded by neuroprotective borders of newly proliferated reactive astrocytes; however, fundamental features of these cells are poorly understood. Here we show that following spinal cord injury or stroke, 90% and 10% of border-forming astrocytes derive, respectively, from proliferating local astrocytes and oligodendrocyte progenitor cells in adult mice of both sexes. Temporal transcriptome analysis, single-nucleus RNA sequencing and immunohistochemistry show that after focal CNS injury, local mature astrocytes dedifferentiate, proliferate and become transcriptionally reprogrammed to permanently altered new states, with persisting downregulation of molecules associated with astrocyte-neuron interactions and upregulation of molecules associated with wound healing, microbial defense and interactions with stromal and immune cells. These wound repair astrocytes share morphologic and transcriptional features with perimeningeal limitans astrocytes and are the predominant source of neuroprotective borders that re-establish CNS integrity around lesions by separating neural parenchyma from stromal and immune cells as occurs throughout the healthy CNS.
- Published
- 2024
50. Glucagon infusion alters the circulating metabolome and urine amino acid excretion in dogs.
- Author
-
Merkhassine, Michael, Coch, Reilly, Frederick, Carol, Bennett, Lucinda, Peng, Seth, Morse, Benjamin, Cummings, Bethany, and Loftus, John
- Subjects
amino acid ,canine ,glucagon ,metabolome ,metabolomics ,Animals ,Dogs ,Glucagon ,Amino Acids ,Metabolome ,Male ,Female ,Chromatography ,Liquid ,Tandem Mass Spectrometry ,Infusions ,Intravenous ,Metabolomics - Abstract
Glucagon plays a central role in amino acid (AA) homeostasis. The dog is an established model of glucagon biology, and recently, metabolomic changes in people associated with glucagon infusions have been reported. Glucagon also has effects on the kidney; however, changes in urinary AA concentrations associated with glucagon remain under investigation. Therefore, we aimed to fill these gaps in the canine model by determining the effects of glucagon on the canine plasma metabolome and measuring urine AA concentrations. Employing two constant rate glucagon infusions (CRI) - low-dose (CRI-LO: 3 ng/kg/min) and high-dose (CRI-HI: 50 ng/kg/min) on five research beagles, we monitored interstitial glucose and conducted untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) on plasma samples and urine AA concentrations collected pre- and post-infusion. The CRI-HI induced a transient glucose peak (90-120 min), returning near baseline by infusion end, while only the CRI-LO resulted in 372 significantly altered plasma metabolites, primarily reductions (333). Similarly, CRI-HI affected 414 metabolites, with 369 reductions, evidenced by distinct clustering post-infusion via data reduction (PCA and sPLS-DA). CRI-HI notably decreased circulating AA levels, impacting various AA-related and energy-generating metabolic pathways. Urine analysis revealed increased 3-methyl-l-histidine and glutamine, and decreased alanine concentrations post-infusion. These findings demonstrate glucagons glucose-independent modulation of the canine plasma metabolome and highlight the dogs relevance as a translational model for glucagon biology. Understanding these effects contributes to managing dysregulated glucagon conditions and informs treatments impacting glucagon homeostasis.
- Published
- 2024
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.